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ABSTRACT
CRAIG JEROME KUTZ. Design of Novel Histone Demethylase Inhibitors as
Drug Candidates to Prevent Cardiac Ischemia-Reperfusion Injury. (Under the
direction of PATRICK WOSTER and DONALD MENICK)	
  
Current therapies to assist short- and long-term outcomes after acute
myocardial infarction (AMI) depend on primary percutaneous coronary
intervention shortly after ischemic insult. Upon reperfusion, localized influx of
oxidative stressors overwhelms the endogenous antioxidant systems and lead to
contractile dysfunction and arrhythmias. The extent of irreversible myocyte
damage during ischemia-reperfusion (IR) injury is a key determinant in patient
outcomes and therefore, strategies to reduce oxidative damage are essential. In
recent years, increasing evidence indicates that epigenetic enzymes such as the
histone demethylases and deacetylases play crucial roles during cardiovascular
disease (CVD). One such enzyme, lysine specific demethylase-1 (LSD1), is
hypoxia-inducible and regulates oxidative balance through epigenetic silencing of
oxidative scavenging enzymes and production of hydrogen peroxide. Our
predominant goal in this dissertation was to develop an LSD1 inhibitor with
enhanced drug-like properties that is well tolerated by cardiac tissue and
cardioprotective during IR. We identified a novel 3,5-diamino-1,2,4-triazoles
scaffold that can be used to design potent, reversible, competitive LSD1
inhibitors that produce little or no overt cytotoxicity. Thus, the central hypothesis
of this dissertation is that novel LSD1 inhibitors with enhanced drug-like
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properties can be used to mitigate cardiac ischemia-reperfusion structural
damage and contractile dysfunction with minimal toxicity to myocytes.
Our approach is innovative in that 1) we will design the first reported
series of potent, reversible competitive inhibitors of LSD1 that display limited
cytotoxicity, and 2) we will identify LSD1 as a new therapeutic target to mitigate
myocardial IR injury. To accomplish this, we will focus on three aims. Specific
Aim 1 - Perform hit-to-lead optimization through structural modification of a new
small molecule scaffold to discover reversible LSD1 inhibitors with suitable
efficacy, negligible toxicity and enhanced drug-like properties. Specific Aim 2 Determine the LSD1 target selectivity, cellular cytotoxicity, and cellular
phenotypic changes in histone methylation of lead compounds. Specific Aim 3 –
evaluate the pharmacodynamic efficacy of a lead 3,5-diamino-1,2,4-triazole
derivative to mitigate post-IR contractile dysfunction and infarction using two
murine models of IR.
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CHAPTER 1: Background and Significance

	
  

1	
  

I. CARDIOVASCULAR DISEASE AND ECONOMIC BURDEN
Cardiovascular disease (CVD) remains one of the leading causes of death
in the United States, contributing to approximately 1 of every 3 mortalities.1 More
than 83 million adults in the United States alone live with CVD, which causes
more than 2,100 deaths per day.2 According to the American Heart Association,
an American experiences a new or recurrent coronary attack (defined as
hospitalized from a myocardial infarction or coronary heart disease attack) every
34 seconds.1 Other than high blood pressure, coronary heart disease has the
highest prevalence rate (6.2%; >20 years old, both sexes) of all CVD.

This

includes an overall 2.8% prevalence of an acute myocardial infarction (AMI).3
Although the rates of CVD in recent years have declined slightly, the economic
burden on the health care system still exceeds $300 billion in direct costs
annually.4 The Center for Disease Control (CDC) reports that for every $6 spent
in the U.S. on health care, $1 accounts for the treatment of CVD.2 This is
astonishing in light of data that indicates these numbers will continue to rise with
the ever-growing geriatric population. The demographic shift alone is estimated
to triple the cost of CVD treatment by 2030.5 To combat this trend, there is a
significant investment in cardiac drug development and prevention of heart
failure, hypertension, lipid disorders and stroke, which has had a profound effect.
For instance, in a study in Health Affairs, medications for blood pressure and
cholesterol alone reduce costs of emergency room visits and inpatient
hospitalizations by $10 per patient according to the CDC.2 Continued research in
cardiac drug development remains a prominent focus of pharmaceutical
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companies, as indicated by the high volume of clinical phase trials for new
therapeutic compounds for CVD.6-7

II. ACUTE MYOCARDIAL INFARCTION AND CLINICAL TREATMENT
The heart is a highly oxidative organ, demanding large amounts of oxygen
consumption to maintain tissue energy demands during contraction.

The

myocardium is supplied by O2 and nutrients through an external vasculature, the
coronary arteries. The coronary arteries branch from the base of the ascending
thoracic aorta and provide energy supply to the cardiac muscle (Figure 1.1).
When functioning normally, the myocardial oxygen consumption (MVO2) can
range from 8-70 ml O2/min per 100g depending on the tissue demand.8 In
comparison, the brain only requires 3 ml O2/min per 100g.

However, an

inadequate supply of O2 to the myocardium resulting from occlusion of blood flow

	
  
Figure 1.1. Coronary Artery Anatomy. The coronary arteries branch from
the base of the ascending aorta. The Left Anterior Descending (LAD) coronary
artery supplies oxygen and nutrients to the Left Ventricle.
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through a coronary artery can result in tissue hypoxia, often characterized
clinically as angina, or chest pain. If this O2 insufficiency is prolonged, irreversible
myocyte damage occurs distal to the region supplied by the occluded coronary
artery, and an AMI results. Depending on the location of anoxia, a multitude of
clinical sequelae can occur, ranging from no visible distress to sudden death.9
Since the 1980’s, a large number of clinical trials demonstrated that
restoration of flow to an occluded coronary artery improved patient morbidity and
mortality following an AMI.10 In particular, reperfusion therapy reduced infarct
damage and sustained left ventricular function if performed within the first 24-hrs.
This was a monumental finding in treatment of AMI because the magnitude of
myocardial infarct damage correlates with a patient’s prognosis and outcome.10
The current standard of care for patients with severe transmural infarctions is
immediate re-establishment of blood flow to the ischemic myocardium, usually
performed by cardiac catheterization.9 This includes treatment by 1) primary
percutaneous transluminal coronary angioplasty and/or 2) thrombolytic therapy.910

Heart Failure and Left Ventricular (LV) Remodeling in AMI:
Recovery from an AMI leads to extensive remodeling of the LV chamber
and architecture, which when left unabated leads to heart failure. In particular,
pathological changes in LV volume and shape are driven by substantial myocyte
hypertrophy, cell death and fibrotic repair.11-12 This adaptive process in cardiac
remodeling is an elaborate response to the severity of infarction caused by an
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AMI. In a clinical trial spanning 35 medical centers across the United States,
Solomon et al. demonstrated that patients with larger infarctions developed larger
LV end diastolic dilation with a loss of systolic ejection fraction, indicating
significant LV remodeling.13 Figure 1.2 shows an example of a clinical
presentation of LV end diastolic dilation.

Figure 1.2. Heart Failure with Reduced Ejection Fraction (HFpEF).
Following an AMI, extensive cardiac remodeling leads to systolic dysfunction.
LV and AV diameter increases (i.e. eccentric hypertrophy) and the myocardial
contractility significantly diminishes. Echocardiograph images taken from
patients seen at the Medical University of South Carolina.
(Courtesy of Dr. Sheldon Litwin, MD, MUSC Cardiology)

	
  

The first stage of LV remodeling takes place within the infarcted tissue.
The necrotic debris and fibrotic scar tissue formed distal to the occluded coronary
artery begins to thin and expand.12 This places an increased demand on remote
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myocardium

outside

of

the

infarct zone, leading to the next
phase of remodeling – eccentric
hypertrophy

and
14

LV

expansion.8,

11,

dilation

is

caused

by
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formed

in-series

Ventricular
new

with existing myofilaments to
improve
compliance,

cardiovascular
an

Figure 1.3. Frank-Starling relationship in
heart failure. Graph represents effect of
systolic dysfunction on stroke volume and
left ventricular end-diastolic pressure,
LVEDP (i.e. preload). Point A – control;
Point B – heart failure.

	
  

adaptive

mechanism to increase stroke volume (SV) and sustain cardiac output (CO).
According to the Frank-Starling relationship between SV and preload (aka LV
end diastolic pressure, LVEDP), this increased SV creates a higher pressure on
the LV (Figure 1.3).8 This is fundamental because wall stress is directly
proportional to LVEDP, which in turn means a higher tissue oxygen demand, and
thus, a lower mechanical efficiency.8
The clinical manifestation of pathological cardiac remodeling is heart
failure. In the benchmark echocardiograph clinical study VALIANT (Valsartan in
Acute Myocardial Infarction), patients with evident LV remodeling following an
AMI had a significantly worse prognosis.15 The earliest understood form of heart
failure following an AMI is defined as left ventricular (LV) systolic dysfunction by
loss of ejection fraction (EF) <0.35 (i.e. heart failure with reduced ejection
fraction, HFrEF).14 Ejection fraction is a measurement of systolic efficiency and is
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calculated by the ratio of SV to LV end diastolic volume (LVEDV). In HFrEF
patients, SV is maintained due to the increased compliance of the myocardium,
but EF is reduced because of increased LVEDV.8, 14

In fact, the loss of cardiac

inotropy, or contractility, is often indicative of systolic dysfunction.

However,

clinical studies with inotropic agents alone produced poor patient improvements
in HFrEF, indicating that systolic dysfunction associated with LVEDV dilation is a
multifactorial pathology.16 Thus, current clinical standard for HFrEF aim to reduce
the load placed on the heart, and thus, ablate LV dilation (e.g. beta blockers,
ACE Inhibitors, angiotensin-receptor blockers).14 Interestingly, more and more
clinical studies indicate that over half of heart failures actually demonstrate
preserved ejection fraction (HFpEF).14 In cohort study of 8,592 middle-aged
patients with heart failure, HFrEF had a higher incidence than HFpEF and lead to
increased mortality (Figure 1.4).17 The pathophysiology and nuances between
HFrEF and HFpEF will not be covered as it is outside the scope of this project.
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Figure	
   1.4.	
   Cohort	
  
Study	
   of	
   HFrEF	
   vs.	
  
HFpEF	
   patients	
   over	
  
11-‐year	
   follow	
   up.	
  
Patient	
   mortality	
   and	
  
heart	
   failure	
   incidence	
  
were	
   reported	
   and	
  
classified	
   by	
   type	
   of	
  
heart	
   failure	
   (i.e.	
   HFrEF	
  
or	
  
HFpEF).	
  
Data	
  
represents	
   8592	
   middle	
  
aged	
   patients	
   nation-‐
wide.	
  	
  
Adapted	
   from	
   Brouwers	
  
et	
   al.	
   Incidence	
   and	
  
epidemiology	
   of	
   new	
  
onset	
   heart	
   failure	
   with	
  
preserved	
   vs.	
   reduced	
  
ejection	
   fraction	
   in	
   a	
  
community-‐based	
  
cohort:	
   11-‐year	
   follow-‐
up	
  
of	
  
PREVEND.	
  
	
   European	
   heart	
   journal	
  
2013,	
  34	
  (19),	
  1424-‐31.	
  

III. ISCHEMIA-REPERFUSION INJURY
Despite the advancements in reperfusion therapy with percutaneous
coronary intervention and thrombolytics, treatment of AMI continues to be
palliative.

Paradoxically,

recannulation

of

occluded

vessels,

either

spontaneously or by therapeutic intervention, causes a secondary wave of
damage to the myocardium, resulting in arrhythmias, mechanical dysfunction,
and myocyte death.18-19 In other words, cell death and cardiac dysfunction occurs
as a result of the initial tissue ischemia that takes place during an AMI, but also
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due to the subsequent reflow of the vascular bed. This detrimental phenomenon
is known as ischemia-reperfusion (IR) injury and can account for up to 50% of
tissue death during an infarction.20 Myocardial death after IR injury can be
attributed to cell apoptosis, necrosis, and autophagy. However, it is still unclear
how much impact on the myocardium each process has individually.

General Pathophysiology/Mechanism of Ischemia-Reperfusion:
Depletion of oxygen supply to cells reduces energy production significantly
by shifting the focus from aerobic respiration (net ~36 ATP) to anaerobic
glycolysis (net 2 ATP). Within minutes, the reduced ATP production causes a
nearly complete abolishment of myocardial contractile force.

If sustained, a

gradual rise in diastolic tension takes place, as myocardial phosphocreatine
stores deplete and Ca2+-mediated crossbridging of myofibrils creates a state of
rigor, or contracture21, and leads to diastolic insufficiency.

In addition, the

increased glycolytic dependency during anoxia causes an accumulation of acidic
byproducts (i.e. lactic acid, H+), lowering the intracellular pH.20 Loss of ATP is
aggravated by a drop in mitochondrial membrane potential, leading to reversal of
the F1F0-ATPase and up to nearly 50% further ATP hydrolysis.22
Upon reperfusion of the previously hypoxic tissue, a complicated cascade
of detrimental ion cycling, mitochondrial dysfunction, oxidative damage and
inflammatory signaling occurs. Through a series of membrane transporters, the
myocardium attempts to normalize the intracellular acidity. The extrusion of a H+
is accompanied by an antiport of Na+ into the cell, creating a transient rise in
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intracellular Na+. This results in reversal of the sarcolemmal Na/Ca Exchanger
(NCX). The significance of this event is the non-stoichiometric counter transport
of a 3 Na+ out of the cell for 1Ca2+ into the cell, leading to a calcium overload
within the myocyte.20
Calcium overload within the myocyte is a hallmark insult during IR injury.
The abundant Ca+ (along with pH homeostasis and ATP insufficiency) leads to
dysregulation of the mitochondrial permeability transition pore (PTP), a key
regulator of mitochondrial membrane potential and mitochondrial integrity.
Mitochondrial damage, along with the sudden influx of O2 to the previously
anoxic tissue, causes a harmful wave of reactive oxygen species (ROS)
formation.
Another hallmark of reperfusion injury is the huge influx of ROS. ROS are
highly reactive molecules that produce lipid peroxidation and sulfyhydryl
oxidation, resulting in membrane leak, intracellular protein changes, and
transcriptional reprogramming.23 ROS radicals include hydrogen peroxide (H2O2),
superoxide (O2-), hydroxyl radical (OH), peroxynitrate (ONOO-), and hydroxyl
ion (OH-). Free radicals contain unpaired electrons in their outermost shells, an
unstable arrangement that react uncontrollably with proteins, lipids, and DNA to
establish an outer stable shell of electrons. Because of their highly reactive
nature, the influx of ROS during IR injury is considered a huge contributor to the
damage caused by reperfusion (Figure 1.5).

In addition, oxidative stress in

cardiomyocytes and vascular smooth muscle causes
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A.

B.

Figure 1.5. Reactive oxygen species (ROS) and tissue damage. (A) ROS
radicals include hydrogen peroxide (H2O2), superoxide (O2-), hydroxyl radical
(OH), peroxynitrate (ONOO-), and hydroxyl ion (OH-). (B) Tissue damage and
dysfunction caused by ischemia-reperfusion and the influx of ROS. Metabolic
disorder caused by low oxygen leading to increased intracellular acidosis.
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decreased efflux of Ca2+ and sequestration of the sarcoplasmic reticulum Ca2+ATPase pump, thus causing additional Ca+-homeostasis dysfunction.
Oxidative damage caused by ROS also creates a non-specific
inflammatory response in the myocardium. The pro-inflammatory cytokine tumor
necrosis factor alpha (TNFα) is released, leading to structural and functional
damage of the tissue. Within the first 24-hours, the innate immunity infiltration of
the tissue (i.e. neutrophils and macrophages) leads to further localized tissue
damage.20 Granulocytes, such as neutrophils, and macrophages are phagocytes
that employ a respiratory burst of ROS to remove necrotic waste. However,
these “internal garbage cleaners” indirectly contribute to the oxidizing agent
milieu within cardiomyocytes during IR.

Apoptosis in Ischemia-Reperfusion Injury:
Programmed cell death is a highly organized series of internal and
external cascades that result in a non-inflammatory cell removal. Apoptosis was
first described in 1972 by Kerr et al. and has since been widely characterized.24
Membrane blebbing, cellular shrinking, nuclear fragmentation, and chromosomal
condensation all take place to form apoptotic bodies that are eventually removed
by the body’s intrinsic immune system.24 In short, downstream signaling of proapoptotic proteins (i.e. caspases, Bad, Bax, Bak, Bid, etc.) leads to the release of
the electron carrier cytochrome c into the cytoplasm and facilitates DNA
damage.25
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Many studies have shown that ablation of apoptosis can lead to reduction
of infarction.

For instance, transgenic knockout studies with a pro-apoptotic

protein Bax show a significant reduction of IR injury in the heart.26 Conversely,
overexpression of the antiapoptitic protein Bcl-2 renders the heart more resistant
to IR insult.27 However, complete ablation of apoptosis is not sufficient for
complete survival from IR, indicating a contributory role of other cell death
mechanisms.

Autophagy in Ischemia-Reperfusion Injury:
An intriguing strategy to limit reperfusion damage and replenish energy
stores within a tissue is conducted through modulation of autophagy. Autophagy
is a dynamic intracellular process used as a quality control by cells to sequester
and recycle damaged cellular components. This is accomplished by isolating
damaged organelles and protein aggregates into lysosomes for degradation and
efflux of macromolecules.25 The up-regulation of lysosomal pathways during
ischemia has been widely characterized.28 Yet, depending on the framework of
activation, it is still unclear whether manipulation of autophagy-related proteins
are beneficial or detrimental during I/R injury.
Many studies indicate that an increase in autophagy is cardioprotective.2829

The depletion of ATP during ischemia induces AMPK-mTOR signaling and

indirectly increases scavenging of high-energy fatty acids and amino acids, thus
recouping

critical

biosynthetic

molecules.30

However,

Valentim

et

al

demonstrated that inhibition of ischemia-induced autophagy leads to improved
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cardiomyocyte survival.31 Similar results were found in ischemic brain injury.32
This may be in part due to prevention of hyperactive autophagy during
reperfusion when ATP/O2 are sufficient. The debate about whether autophagy is
cytoprotective or cytotoxic is still under investigation.

Necrosis in Ischemia-Reperfusion Injury:
Necrosis is another form of cell death, but is considered “uncontrolled” or
external cell injury because of the significant inflammatory response associated
with it. Contrary to apoptosis, necrosis is often caused by an external insult (i.e.
toxins, infections, or trauma). Initially, the cells begin to swell and the nucleus
degrades. Soon after, membrane disruption and rupture lead to a release of
localized inflammatory cytokines and as a result, cause immune system
infiltration.25 Because of the associated membrane rupturing, biochemical
markers of an AMI typically measured in the clinical, such as troponin or creatine
kinases, are thought to be due to myocyte necrosis.

Although IR

pathophysiology is considered a more orchestrated cell death by apoptosis, an
extent of irreversible necrosis still occurs and leads to a localized inflammatory
reaction.

Protection Strategies – Preconditioning:
An effective method to reduce the damage caused by IR is by the
phenomenon of ischemic preconditioning.33-34 In short, this method of protection
for IR damage entails mechanical exposure of tissue to short, nonlethal periods
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Figure 1.6. Cardiac Ischemia-Reperfusion injury and pharmacologic
preconditioning. Adapted from Garcia-Dorado, D. and Piper, H. M.,
Postconditioning: reperfusion of "reperfusion injury" after hibernation.
Cardiovascular research 2006, 69 (1), 1-3.
of ischemia that attenuate damage of further IR insults. Although studies in
rodents show substantial benefits in mechanical preconditioning, the positive
effect has not successfully translated to the clinic.35 For decades, researchers
have tried to mimic mechanical preconditioning by pharmacologic manipulation of
protective survival signaling. However, new insight into pathways that governs
preconditioning provides new strategies to develop successful therapeutic targets
for pharmacological intervention (Figure 1.6).
The protection provided by preconditioning is biphasic – an early phase of
preconditioning and a more chronic phase. The early window occurs within 1hour of preconditioning and does not appear to depend on protein synthesis.36
Thus, “early preconditioning” is contingent on manipulation of post-translational
modification of cell signaling molecules that act against programmed cell death or
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activate endogenous cell survival maintenance programs. These include
phosphorylation, methylation, and acetylation of effector molecules. Posttranslational modifications influence a protein’s conformation, dictate their
location within the cell, alter interactions with other proteins, and adjust activity of
signaling.

Because early preconditioning is exhausted quickly, research has

focused on the fluidity of signaling cascades to induce protection.37 For example,
activation of PI3K and its downstream targets Akt, p70S6K, and ERK1/2 have
been deemed the Reperfusion Injury Survival Kinase (RISK) pathway.38 Other
cell signaling effector molecules shown to induce preconditioning include
mTOR37, eNOS/NO39, inhibition of PKC-ε, and inhibition of GSK40. Cell survival
signaling stabilizes the endoplasmic reticulum41, ablates cell death programs (i.e.
Bax/Bad/Bcl2)42, increases antioxidants (i.e. SOD2 and Catalase)23,

43

, and

activates repair factors (i.e. HIF-1α).44 Late phase preconditioning, on the other
hand, conveys protection from IR up to a few days.45 Although many of the same
pathways in early preconditioning are also affected in late phase, the longevity of
late phase indicates de novo synthesis of cardioprotective proteins.
Preconditioning

provides

the

greatest

potential

for

therapy

by

reprogramming the myocardium into a “defensive phenotype” from IR damage. In
recent years, research in the field of epigenetics has linked the biphasic nature of
preconditioning. Epigenetics is a unique regulatory network of enzymes for
genome and non-genome protein regulation and will be discussed in further
detail later.
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IV. EPIGENETICS: DYNAMIC REGULATION OF THE GENOME
In the late 1980ʼs and early 1990ʼs, the human genome project was an
enormous undertaking that was predicted to revolutionize the way the medical
field conducted patient-oriented healthcare. However, certain recent nuances in
the complexity of gene regulation made this mission exceedingly difficult. Until
recently, a dichotomy existed as to why genetically identical, monozygotic-twins
exhibited different susceptibility to diseases. One widely accepted explanation for
these genotype-independent changes in phenotype is that the environment plays
a key role in disease susceptibility – the age-old debate of “nature versus
nurture”. In the past two decades, the rapidly expanding field of epigenetics
demonstrated that the human genome is extremely dynamic in its ability to
change gene expression and not confined to the sequence of base pairs within
the DNA. Epigenetic regulation of gene expression focuses on dynamic
modifications of histones, DNA, and microRNAs that are flexible enough to
respond to internal and exogenous environmental stimuli and change the genetic
landscape independent of the genome.46 Put simply, the field of epigenetics
reminds researchers that a simple arrangement of sugar-containing base pairs is
just the tip of the iceberg in understanding the human genome.
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Human DNA is composed of over 3 billion nucleotide pairs, making it
nearly 5 feet long.

Storage of such a vast amount of genetic data in a

micrometer-sized cell is accomplished by a series of structural packaging
strategies

involving

histones

(Figure

1.7).

Histone

proteins

occur

as

heterooctamers that consist of one H3-H4 tetramer and two H2A-H2B dimers.
These proteins interact with double stranded DNA in such a way that
approximately 146 base pairs of DNA are wrapped around the histone octamer to
form nucleosomes. The lysine-containing tails of histones, consisting of up to 40
amino acid residues, protrude through the DNA strand, and act as a site for posttranslational modification of chromatin. The affinity of DNA for each histone
independently governs the ability of transcriptional machinery to read the genetic
code. This higher order of transcriptional regulation creates physical limitations
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through the winding and unwinding of DNA within nucleosomes. Euchromatin is
chromatin loosely packed around histones, and thus, is spatially oriented in a
transcriptionally active conformation. On the contrary, heterochromatin is tightly
packaged, creating a steric hindrance for trans-acting transcription factors and
effectively silencing genes in the region.
The dynamic interplay between histones and chromatin conformation is
critical for selective control of gene expression, and chromatin-remodeling
enzymes have now become attractive therapeutic targets for multiple diseases
with an epigenetic basis. Epigenetic histone enzymes are capable of
manipulating nucleosomes between states of heterochromatin and euchromatin,
and thus, effectively controlling gene transcription. For instance, a number of
post-translational histone residue modifications are known to control gene
expression, including methylation, acetylation, ubiquitination, sumoylation, ADPribosylation and phosphorylation.47 Table 1 demonstrates how post-translational
methyllysines and acetyllysines on different histone residues can influence gene
transcription.
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Activation
Repression
Repression
Elongation
Elongation
Elongation

H3-Lysine 27 (H3-K27)
H3K27me
H3K27me2
H3K27me3

H3-Lysine 36 (H3-K36)
H3K36me
H3K36me2
H3K36me3

SET2, NSD1, SMYD2

EZH2

Histone Acetyltransferase (HATs)

FBXL10, FBXL11, JMJD2A,
JMJD2B, JMJD2C

UTX, JMJD3

Histone Deacetylases (HDACs)

LSD1, JMJD1A, JMJD1B, JMJD2A,
JMJD2B, JMJD2C, JMJD2D

LSD1, JARID1A, JARID1B,
JARID1C, JARID1D, FBXL10

Histone Demethylases

!"#$#!%&%!"'()*+#!",#$#-.!"'()*+#!"/#$#'0.!"'()*+#12"')*#$#12"')*1'.%&

Other Modifications Not Listed: H3K79me1-3, H3K14acetyl, H4K20me, H2BK5me1/3, H3R2/17/26me, H4R3me, H3S10

Repression

Activation
Repression
Repression

H3-Lysine 9 (H3-K9)
H3K9me
H3K9me2
H3K9me3
H3K9acetyl

MLL1, MLL2, MLL3, MLL4, MLL5,
hSET1A, hSET1B, ASH1

Activation
Activation
Activation

SUV39H1, SUV39H2, G9a,
EuHMTase, SETDB1

Histone Methyltransferases

Genetic
Regulation

Histone
Mark
H3-Lysine 4 (H3-K4)
H3K4me
H3K4me2
H3K4me3

Histone H3 Modifications

Table 1. List of histone modifications, enzymes and their epigenetic phenotype.

Epigenetics in Cardiovascular Disease:
Various types of CVD have long been described as familial diseases. Yet,
studies of monozygotic twins suggest that the genome is not an all-or-none
determinant of disease incidence.48-49 In recent years, increasing evidence
indicates that epigenetic factors may be driving CVD and therapeutically targeting
these enzymes can limit the pathogenesis of atherosclerosis, angiogenesis, IRinjury, cardiac hypertrophy and heart failure, just to name a few.50
Epigenetic control of genes by histone manipulation can be used to
reverse detrimental transcriptional changes during CVD. One example to prevent
the damaging increases in H2O2 and O2- during IR injury is by enhancing the
endogenous antioxidant enzymes catalase and SOD2.43, 51 In particular, these
promoters can be modulated through epigenetic enzymes.51-52 Yet, another
example of epigenetic control is the endothelial response to hypoxia and sheer
stress during angiogenesis and AMI. The NOS3 promoter encodes eNOS, which
catalyzes the formation of the potent vasodilator nitric oxide (NO).53 NO can react
with ROS species to form reactive nitrogen species, another toxic metabolite that
causes cellular damage.53
Extensive research has demonstrated the therapeutic potential of
targeting epigenetic enzymes in CVD.54 The specific epigenetic modifiers and
their individual roles in CVD will be discussed in further detail in the next section.
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V. EPIGENETIC ENZYMES – ERASERS AND WRITERS
Lysine Specific Demethylase-1 (LSD1/KDM1A)
Until 2004, methylation of histones was considered an irreversible event,
much akin to DNA methylation of CpG islands.55 Shi et al. challenged this notion
with their discovery of the flavin-dependent amine oxidase lysine specific
demethylase 1 (LSD1, also known as KDM1A or BHC110).55 For the first time, an
enzyme was shown to remove methyl groups from the ε-amino group of lysine
residues in the histone tail. Several histone residues contain mono-, di-, and trimethylation of lysine residues (H3K4, H3K9, H3K27, H3K36, H3K79, H4K20).
Notably, the landscape of various methylation marks dictate chromatin packaging
and cellular phenotype. LSD1 preferentially catalyzes the removal of mono- and
dimethylated forms of the activating mark H3K4 (H3K4me1, H3K4me2) to
repress gene transcription (Figure 1.8B).55-56 However, LSD1 demethylation of
the deactivating marks H3K9me1/2 have also been reported in an androgen
receptor-mediated event, resulting in up-regulation of a gene.57 Thus, LSD1
activity can play multiple roles in gene regulation.
Recently, a noncanonical function of LSD1 in demethylation of nonhistone proteins has been described. For instance, the tumor suppressor protein
p53 is post-translationally modified at lysine 370 (K370).58 Monomethylation at
this residue stabilizes p53 and prevents its ubiquitination. Also, dimethyl-K370
(K370me2) facilitates binding of p53 to 53BP1, a cofactor used to shuttle and
activate p53. LSD1 demethylates K370me2 to K370me and promotes
degradation of p53.59 Therefore, LSD1 can repress pro-apoptotic functions of
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downstream p53 signaling.

LSD1 also has been shown to stabilize DNA

methyltransferase (DNMT1) through manipulation of lysine residue methylation.60
Clearly, LSD1 can play a huge role in protein regulation outside of its traditional
histone function.
LSD1, as well as all flavin-containing amine oxidases, catalyze the
oxidation of an amine-containing lysine residue using molecular oxygen as the
electron acceptor (Figure 1.8B).61 During the initial removal of the histone tail
methyllysine substrate, the α-CH is oxidized by the FAD prosthetic group to form
an imine intermediate. Reduced FAD, in turn, is oxidized by molecular oxygen to
produce a hydrogen peroxide byproduct. The resulting imine intermediate is then
non-enzymatically

hydrolyzed

to

form

the

demethylated

substrate

and

formaldehyde. Regeneration of the oxidized form of FAD then produces
hydrogen peroxide.56, 61-62
LSD1 is a very large, asymmetrical protein (~110kDa) that contains three
structural domains – an amine oxidase catalytic domain, a SWIRM domain, and
a long helical tower domain (Figure 1.8A).63 The C-terminus amine oxidase
domain contains the cofactor FAD and is the site of demethylation. In close
proximity, the N-terminus SWIRM domain is a highly conserved DNA binding
domain.64 Extending from these is the tower domain, a long helix-turn-helix motif
used primarily for the extensive protein binding interactions of LSD1. In
particular, extensive crystal structures demonstrate the close intermolecular
relationship between LSD1 and the multidomain corepressor protein, CoREST.63
CoREST contains long α-helical motifs that bind with high affinity to the structural
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tower domain of LSD1, rendering LSD1 more resistant to proteosomal
degradation.62-63 In addition, this interaction facilitates an LSD1 conformation that
favors the H3K4 substrate.62
LSD1 and CoREST also associate with HDAC1/2 and BHC80 in this large
co-repressor complex (Figure 1.8C). Interestingly, the close interaction and
crosstalk between binding partners within this LSD1:CoREST:HDAC1/2 complex
influence individual catalytic activity. For instance, LSD1 is more active against
hypoacetylated nucleosomes and acetylation of H3K9 causes a nearly 6-fold
increase in Km value for an N-terminal histone tail.65 In other words, deacetylation
of acetyl H3K9 by HDAC1/2 facilitates LSD1-catalyzed demethylation.65 Similarly,
Zhang et al. showed that hyperacetylation of lysine tails caused a concurrent
increase in methylation of histones.66 In recent years, this interdependency
between epigenetic enzymes has been a focus of therapeutic targets and
continues to be an intriguing, yet fairly unexplored, method to treat disease.67
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Figure 1.8. Lysine Specific Demethylase-1. A.) LSD1-CoREST crystal structure (PDB: 2V1D) showing the
tower domain interaction, DNA-binding domain SWIRM, and the amine oxidase domain. B.) LSD1 catalytic
mechanism using cofactor FAD and production of byproduct H2O2 and formaldehyde. C.) LSD1:CoREST:HDAC1
corepressor complex regulates gene transcription.
	
  

Because LSD1 is overexpressed in a number of human cancers (e.g.
acute myeloid leukemia, neuroblastoma, retinoblastoma, prostate cancer, breast
cancer, lung cancer and bladder cancer),68-71 the protein is traditionally an
important target for antitumor agents.72 However, new emerging roles for LSD1 in
disease pathogenesis other than cancer are being reported.73-77 Of particular
interest to IR injury, LSD1 was shown to play a direct role in the DNA damage
response and is recruited to sites of DNA damage through the interaction with E3
ubiquitin ligase RNF168.78 In addition, LSD1 can generate a local burst of H2O2
and formaldehyde that induce oxidative damage of nearby DNA residues.79 In the
past half-decade, histone demethylases have been implicated in CVD only a
handful of times. In 2011, Zhang et al. became the first to identify a histone
demethylase as the key regulator in the reprogramming of gene expression
associated with cardiac hypertrophy.80 Subsequently, LSD1 itself was shown to
regulate

vascular

function

and

blood

pressure

during

salt

sensitive

hypertension.81 Since these findings were reported, little additional work as been
done in this area.
The close functional and structural epigenetic binding partner (i.e. Class I
HDACs) has been extensively studied in CVD and IR injury (Discussed in more
detail under “Histone Deacetylases”).51 Therefore, since HDAC inhibitors have
shown preclinical efficacy for limiting cardiac IR damage, we proposed that
targeting their close counterpart, LSD1, might also provide efficacy for IR Injury.
To date, this hypothesis has not been tested, but increasing evidence indicates
that LSD1 may play a role in IR damage. For instance, LSD1 appears to be
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inducible and responsive to hypoxia.82-83 During ischemic brain injury, LSD1
expression was induced in a region and cell specific fashion after cerebral IR that
coincided directly with changes in H3K4 methylation.82 Likewise, hypoxia-induced
silencing of BRCA1 promoter in breast cancer is mediated by LSD1.83 Evidence
also suggests that LSD1 may contribute to the oxidative environment through
direct production of ROS and silencing of antioxidant enzymes.52 It is recruited to
the superoxide dismutase (SOD2) promoter in diabetic retinopathy to suppress
SOD2 expression through modulation of H3K4 methylation.52 Therefore, we
hypothesize that LSD1 may be a novel target that plays an important role in
cardiac IR injury.

Histone Deacetylases (HDACs)
Histone deacetylases represent a large class of histone erasers
responsible for the post-translational removal of an ε-N –acetyl moiety from
specific lysine residues on the histone tail, thus preventing recruitment of transacting transcription factors. As a result, HDACs repress gene transcription.84 In
addition, a large number of non-histone substrates are known.85 These well
characterized epigenetic enzymes have been considered to play a role in CVD
pathology for years. Most importantly, ischemia induces HDAC activity in the
heart.19 Therefore, many studies have shown the efficacy of HDAC inhibition to
attenuate cardiac IR injury.19, 29, 51
In brief, the 18 isoforms of HDACs are divided into four classes. Class I,
II, and IV are the zinc dependent metalloproteins and class III comprise the
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NAD+-dependent sirtuins.84 Of particular interest, the class I HDACS (1, 2, 3, and
8) are small nuclear histone erasers that cooperate in discrete co-repressor
complexes, one of which (i.e. CoREST/REST) incorporates LSD1.86 The
crosstalk between LSD1 and HDACs has been discussed above (see “Lysine
Specific Demethylase-1”). Only recently has the significance of a class-specific
HDAC inhibitor been applied to cardiac IR.51 In fact, class I specific HDAC
inhibitors sustained cardiac function and ablated infarction following IR injury in
an ex vivo isolated rat heart model.51 However, isoform-specific (as opposed to
class-specific) HDAC inhibitors do not exist, although many have been
developed that show a preference for a given HDAC isoform. Therefore, the
propensity for off-target effects mediated by inhibition of multiple isoforms can
complicate mechanistic studies.

Histone Methyltransferases and Acetyltransferases
The early dogma for gene regulation was that post-translational
acetylation and methylation of histones and DNA was irreversible. However, the
discovery of epigenetic erasers (i.e. HDACs, histone demethylases, etc.)
revolutionized our understanding of transcriptional regulation.87 In fact, the
epigenetic landscape is a vastly dynamic environment, and gene expression is
modulated through freely reversible enzymatic processes. It is worth noting that
large

families

of

histone

methyltransferases

(HMTs)

and

histone

acetyltransferases (HATs) are also crucial in regulating gene transcription. For
instance, both HMTs and HATs transfer a methyl or acetyl residue, respectively,
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onto the ε-nitrogen of a specific lysine residue.88 Importantly, activities of HMTs
and/or HATs have been implicated in CVD.89-90 These enzymatic transformations
confer reversibility to post-translational modifications of histones and the
mechanisms discussed for LSD1 and HDACs. However, these epigenetic writers
will not be discussed in any further detail.

VI. OTHER FLAVIN-DEPENDENT AMINE OXIDASES
The amine oxidase enzymes all contain evolutionarily conserved FADdependent catalytic pockets. Each enzyme oxidizes biogenic amines (primary,
secondary, and tertiary) into imine intermediates and produces H2O2 and
aldehyde byproducts, as described earlier. Each amine oxidase adapted
specialized motifs and cellular localization, giving them different biological
functions. The amino acid sequences within the active sites demonstrate similar
architecture, with the FAD prosthetic cofactor in close proximity of a lysinecontaining residue.

LSD1 uniquely adapted a SWIRM and tower domain to

facilitate its interaction with chromatin.91 Figure 1.9 demonstrates the close
homology between catalytic mechanisms of LSD1 and another amine oxidase,
spermine oxidase (discussed further below).

	
  

29	
  

Figure 1.9. Homology between amine oxidase family: Lysine Specific
Demethylase-1 and Spermine Oxidase. Oxidation by FAD cofactor (yellow)
results in an imine intermediate (purple) and the byproduct hydrogen peroxide
(orange). Non-enzymatic hydrolysis leads to the formation of the final
substrate and a reactive aldehyde (green).

	
  

VI.a. Spermine Oxidase and Polyamine Metabolism
The origin of LSD1 discovery (previously known as KIAA0601) can be
traced back to work by Shi et al. and their observation of sequence homology
with common amine oxidases.55 In particular, the prior perception of KIAA0601
was as a polyamine oxidase that reflected an additional role in lysine
demethylation.

Since then, the characterization of LSD1’s biochemical

mechanism has diverged significantly from the polyamine oxidases. However,
significant off-target implications of current synthetic LSD1 inhibitors fail to
consider polyamine oxidases in their screens. Clearly, the close homology of
LSD1 to the polyamine oxidases, such as spermine oxidase, merits further
consideration as a potential off-target enzymes.
	
  

30	
  

	
  
Figure 1.10. Diagram of polyamine metabolic pathway. Polyamine
biosynthesis (blue) starts from the conversion of L-ornithine by ornithine
decarboxylase (ODC) to make putrescine. The end product is the highly
charged spermine. Backconversion catabolism of polyamines (red) proceeds
by the oxidation of spermine by spermine oxidase (SMO). The 3aminopropanal byproduct from this oxidation can produce the highly reactive
aldehyde, acrolein. Acrolein will then produce protein adducts on lysine
residues, Nε-(3- formyl-3,4-dehydropiperidino)lysine, or FDP-lysine.

	
  

Polyamines are ubiquitous, highly charged species and are essential in
homeostatic cell growth, differentiation, and death.92 They include putrescine,
spermidine, and spermine (Figure 1.10). For several decades, manipulation of
the intracellular level of polyamines has been a key strategy to modulate cell
growth.
	
  

For

instance,

it

is

well

characterized
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that

higher

polyamine

concentrations contribute to actively growing cells, whereas depletion are typical
of quiescent cells.93 Polyamines contain highly protonated amines at physiologic
pH, and thus, bind profusely to negatively charged species within the cell,
including DNA, membrane bound lipids, and negatively charge proteins.94 As
such, they often facilitate protein:protein and protein:nucleic acid interactions
(e.g. transcription factor binding to DNA). In addition, polyamines can stabilize
membranes against lysis95, prevention of mitochondrial damage by sustaining
respiratory control96, and have anti-inflammatory action through suppression of
vascular permeability.97 In fact, the end product in the polyamine synthetic
pathway (i.e. Spermine) prevents generation of reactive hydroxyl radicals and
acts as a potent antioxidant.94
Fundamental

polyamine

biosynthesis

is

initiated

by

ornithine

decarboxylase (ODC), which catalyzes arginine and L-ornithine decarboxylation
to form putrescine.98 Sequential addition of an aminopropyl group to putrescine
and

spermidine

are

performed

to

produce

spermidine

and

spermine,

respectively. This reaction is catalyzed by their respective synthases and
decarboxylated S-adenosyl-L-methionine (dcSAM) to complete the synthetic
portion of the polyamine pathway.99
Polyamine catabolism is also a highly regulated process. Spermine and
spermidine are each acetylated by spermine/spermidine-N1-acetyltransferase
(SSAT) and then oxidized by polyamine oxidase (PAO) to produce putrescine.99
Similar to other amine oxidases, this process yields hydrogen peroxide and a
reactive aldehyde.
	
  

Most importantly, the backconversion of spermine to
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spermidine is facilitated by the recently characterized amine oxidase, spermine
oxidase (SMO).98
Of particular interest, accumulating evidence in polyamine metabolism
implicates a role during ischemia-reperfusion injury. SMO and SSAT are upregulated during kidney and hepatic IR injury, leading to depletion of spermine
and spermidine with a dramatic increase in the backconversion end product,
putrescine.100 In the heart, Han et al. demonstrated that within myocardial
infarcted tissue, there was temporal depletion of spermine and spermidine, which
they found were due to overexpress SSAT and ODC.101 This is key in itself
because spermine is a natural antioxidant and anti-inflammatory agent.94 In fact,
exogenous spermine given to an isolated rat heart after 40-min of global
ischemia caused in improvement in cardiac hemodynamic parameters (i.e.
LVDP, LVEDP, and +/-dP/dt) when reperfused for 30-minutes.102
Consequently, during IR injury, the enhanced polyamine backconversion
increases the pool of putrescine and generates toxic byproducts H2O2 and 3aminopropanal (Figure 1.10).98, 100 3-aminopropanal is in itself cytotoxic, but can
be metabolized into other highly reactive aldehydes, including acrolein.103 The
unsaturated aldehyde readily generates protein adducts on lysine residues, Nε(3- formyl-3,4-dehydropiperidino)lysine, or FDP-lysine, and can lead to
irreversible membrane disruption, mitochondrial damage, oxidative stress and
cell death.103
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VI.b. Monoamine Oxidases
Among the most highly characterized members of the amine oxidase
family are the monoamine oxidases A and B (MAO-A, MAO-B). MAO-A is highly
abundant in cardiomyocytes.104 The mitochondrial membrane bound MAOs play
an important role in catecholamine and serotonin metabolism. In addition, the
heart is sensitive to chronic neurohormonal stimulation and peripheral
hemodynamic stress, both processes that produce extensive epinephrine,
norepinephrine, and dopamine.105 Like other amine oxidases, oxidation of these
substrates creates H2O2 production, which can facilitate cell apoptosis.106 During
hemodynamic or hypertrophic stress, circulating/tissue levels of catecholamines
increase, subsequently causing MAO-derived H2O2 overproduction.107 As a
result, multiple studies have used MAO-inhibitors to decrease oxidative damage
and

improve

cardiac

function

during CVD.108-109 Oxidative stress
caused by MAO-A on the outer
mitochondrial membrane results in
mitochondrial

uncoupling

and

further ROS release, leading to
tissue

damage

and

contractile

dysfunction (Figure 1.11).105

	
  
Figure 1.11. Monoamine oxidase
activity on mitochondrial membrane
creates oxidative damage during IR.

	
  

Although the scope of this dissertation does not include a discussion of
the role of MAO inhibition in cardioprotection, LSD1 inhibitors have the potential
to produce significant off-target effects involving MAO.56 The therapeutic risk and
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adverse side effects of MAO inhibition (e.g. nausea, drowsiness, lightheaded,
malignant hypertension, sleep disturbances, etc.) caused by their large
involvement in the neuroendocrine system make them undesirable targets.

VII. SYNTHETIC AMINE OXIDASE INHIBITORS
VII.a. Lysine Specific Demethylase-1 Inhibitors
To date, a number of small molecule inhibitors of LSD1 have been
described, as shown in Figure 1.12. Because the FAD/amine-oxidase domain of
LSD1 shows considerable sequence and structural homology to MAO-A and B,
the earliest inhibitors of LSD1 focused on scaffolds similar to traditional MAO
inhibitors. Lee et al. demonstrated the ability of several MAO inhibitors to reduce
nucleosome demethylation by recombinant LSD1/CoREST.110 Although selective
MAO inhibitors (i.e. pargyline, clorgyline) showed limited ability to reduce LSD1
activity, nonselective MAO inhibitors demonstrated substantial efficacy.

Both

phenelzine (1) and tranylcypromine (2) successfully inhibited LSD1/CoREST.110
In fact, tranylcypromine revealed an enzymatic IC50 < 2µM and effectively
increased in vitro global H3K4me2 in P19 embryonic carcinoma and derepression of LSD1 target genes Erg1 and Oct4.110 Tranylcypromine is an
irreversible, mechanism-based inhibitor that covalently binds FAD, either through
a modification of FAD to form cinnamaldehyde-FAD and/or atropaldehydeFAD111, an FAD-heterocyclic pyrrolidine adduct112, or N(5) intermediate FAD
adduct.113 LSD1 inhibitors based on the tranylcypromine
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Figure 1.12. Structures of amine oxidase inhibitors. 1, phenelzine; 2,
tranylcypromine; 3, GSK-LSD1; 4, (bis)guanidines; 5, (bis)biguanides; 6, [K4Met]-21mer peptide; 7, γ-pyrone Namoline; 8, N'-(1-phenylethylidene)benzohydrazides; 9, N3-(2-chloro-6-phenoxybenzyl)-4H-1,2,4-triazole-3,5diamine; 10, N3,N5-bis(2-methoxybenzyl)-1H-1,2,4-triazole-3,5-diamine; 11,
MDL-72527; 12, guazatine.
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scaffold have been produced and characterized, and in March 2015, the first
phase-I clinical trial of an LSD1 inhibitor (ORY-1001) was started for the
treatment of acute myeloid leukemia.114 Shortly thereafter, a second clinical trial
was

begun

involving

the

tranylcypromine-based

inhibitor,

GSK-LSD1/

GSK2879552 (3), which is a highly specific and potent LSD1 inhibitor with an IC50
of 16 nM and >1000 fold selectivity over LSD2, MAO-A, and MAO-B.114
A small number of effective LSD1 inhibitor classes have been discovered
that are based on scaffolds other than the tranylcypromine backbone.

For

instance, our lab hypothesized that due to the structural similarity of LSD1 to the
polyamine oxidases SMO and APAO, long chain oligoamine homologues could
also act as LSD1 inhibitors. A series of (bis)guanidine (4) and (bis)biguanide (5)
analogues originally designed as anti-trypanosomal agents acted as noncompetitive LSD1 inhibitors at concentrations <2 µM.115-117 Most importantly,
these polyamine mimics were the first compounds that were shown to increase
H3K4 methylation, and to re-express epigenetically silenced tumor supressors
(i.e. SFRP1, SFRP4, SFRP5, and GATA5).118 Additional functionalized isosteric
(bis)ureidopropyl and (bis)thioureidopropyldiamine derivatives with 3-5-3 and 3-63 carbon backbones also demonstrated relative potency.119 Similar functional
moieties were reported by Dulla et al. using functionalized phenyl oxazole
derivatives, although they exhibited only moderate potency.120
Although inhibitors based on a linear peptide backbone are susceptible to
hydrolysis and difficult to deliver, many highly potent compounds have been
reported.121-122 Forneris et al. described a 21-mer peptide (6) that is analogous to
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the H3K4 substrate region of LSD1, wherein Lys4 was replaced by a methionine.
This linear peptide was a potent inhibitor of recombinant LSD1 with a Ki value of
0.04 µM, and of LSD1 bound to CoREST with a Ki value of 0.05 µM.121 More
recently, cyclic peptide analogues with lactam bridges between Lys5 and Glu10
of the 21-mer were developed, and these compounds were significantly more
stable to hydrolysis in rat plasma and revealed competitive inhibition of LSD1 (Ki
= 385 µM).123
Despite the recent flurry of LSD1 inhibitor discovery efforts, most utilize
latent electrophilic scaffolds that produce irreversible, mechanism-based
inactivation of LSD1,56 and very few reversible inhibitors have been reported.
Irreversible, or suicide inhibitors, typically bind covalently to proteins and
generally have extended half-lives. Thus, they are more likely to produce offtarget effects mediated through other enzymes.

By contrast, if a reversible

inhibitor produces off-target toxicity, it can be alleviated by administration of high
concentrations of the natural substrate. Therefore, in epigenetically driven
disorders where cytotoxicity is not a desired endpoint, such as CVD, reversible
inhibitors are preferable.
Willmann et al. utilized a virtual screen of a natural product-inspired library
to identify the γ-pyrone namoline (7), which acts as a competitive, reversible
inhibitor of LSD1 (IC50 = 50 µM).124 In addition, small molecule peptidomimetics
have been published as reversible compounds, but only show in vitro phenotype
changes in substrate at 1 mM.125 Recently, a novel class of N'-(1phenylethylidene)-benzohydrazides was characterized as highly selective,
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reversible LSD1 inhibitors.126 These highly potent (Ki = 31 nM) compounds
typified by 8 produced significant anti-proliferative ability in several cancer cell
lines, albeit within the low micromolar range. This suggests that the in vitro
activity in cancer cells may be a substantial off-target effect. In addition, the core
N′-(2-hydroxybenzylidene)hydrazide motif has previously been characterized as
a frequent hitter in many biochemical assays.127 Enzyme kinetic studies revealed
that these analogues produce non-competitive inhibition, meaning the inhibitor
may not prevent the enzyme from binding to its substrate by occupying the active
site.

VIII.b. Spermine Oxidase Inhibitors
Because polyamines play significant roles in mammalian cells, it is not
surprising that disruption of one polyamine metabolic enzyme can have countless
cellular effects. Several groups have identified amines, guanidines or similar
analogues that act as selective inhibitors of APAO and SMO. The most widely
used polyamine modulator was designed in 1985 as a butadienyl putrescine
derivative.128 N,N-bis(2,3-butadienyl)-1,4-butanediamine, also known as MDL
72,527 (11), is a potent inhibitor of murine PAO,129 as well as human APAO and
SMO, but does not inhibit MAO.130-131 Cona et al. demonstrated that guazatine
(12) is a non-competitive inhibitor of maize PAO and can selectively inhibit
human recombinant APAO and SMO.132 Other guanidines, such as the
(bis)guanidines

and

(bis)biguanides

described

earlier

(“Lysine

Specific

Demethylase-1 Inhibitors”), produced significant inhibition of SMO (42% at 10
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µM) and APAO (92% at 10 µM).117 To date, a limited number of SMO inhibitors
have been identified and MDL 72,527 continues to be used as a standard in
research.

VIII. SPECIFIC AIMS
To date, no standard therapy exists that can mitigate the injury caused by
reperfusing an occluded coronary artery after an AMI. In fact, up to 50% of total
infarct damage is attributed to IR injury. Upon reperfusion, a secondary wave of
damage leads to contractile dysfunction and arrhythmias. The extent of
irreversible myocyte damage is a key determinant in patient short- and long-term
outcomes and therefore, the need for therapies to reduce IR injury are apparent.
However, pharmaceutical strategies to reduce IR damage have yet to translate
successfully into the clinics.
In recent years, increasing evidence indicates that epigenetic enzymes
such as the histone demethylases and deacetylases play crucial roles during
CVD. One such enzyme, LSD1, is hypoxia-inducible and regulates oxidative
balance through epigenetic silencing of oxidative scavenging enzymes and
production of H2O2. Yet, the role LSD1 and other demethylase enzymes play in
cardiac IR has yet to be explored. Our overall goal is to validate LSD1 as a novel
therapeutic target, and to discover a new series of potent, reversible inhibitors
that are well tolerated by cardiac tissue.
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The CENTRAL HYPOTHESIS of this dissertation is that novel LSD1
inhibitors with enhanced drug-like properties can be used to mitigate
cardiac ischemia-reperfusion structural damage and contractile
dysfunction with minimal toxicity to myocytes.

In order to test this hypothesis, we pursued the following Specific Aims:
Specific Aim 1. Perform hit-to-lead optimization through structural
modification of a new small molecule scaffold to discover reversible LSD1
inhibitors with suitable efficacy, negligible toxicity and enhanced drug-like
properties. A virtual screen using recombinant LSD1/CoREST crystal structure
(PDB 2D1V) was used to identify two hit compounds, (9 and 10), that were
shown to act as potent, selective and nontoxic LSD1 inhibitors in vitro.133 We will
use a structure-based drug design approach to produce a focused library of 3,5diamino-1,2,4-triazole analogs that will be screened as LSD1 inhibitors.
Compounds
functionalized

will

be

synthesized

N-substituted

by

heterocyclization

N’-cyano-S-methylisothiourea

of

appropriately

and

hydrazine.

Screening for in vitro activity against recombinant LSD1/CoREST will be
performed using an HRP-coupled fluorometric assay. For selected compounds,
kinetic constants (Ki and Vmax) and binding affinity values will be measured by
isothermal titration calorimetry.

Specific Aim 2. Determine the LSD1 target selectivity, cellular cytotoxicity,
and

cellular

phenotypic

changes

in

histone

methylation

of

lead

compounds. Many known LSD1 inhibitors are based on the irreversible pan	
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amine oxidase inhibitor tranylcypromine, a clinical MAO inhibitor. It is challenging
to design a TCP-based LSD1 inhibitor for clinical use that is specific, has low
toxicity, and is devoid of the many biological responses as TCP itself. Therefore,
the purpose of this aim will be to identify LSD1-specific inhibitors from
compounds produced in Specific Aim 1. LSD1 inhibitory activity will be compared
to inhibition of MAO-A and MAO-B using a commercial kit to determine a
selectivity index and cytotoxicity will be evaluated using a standard MTS
reduction assay. Inhibitors meeting pre-determined criteria (50-fold LSD1
selectivity, IC50 <5µM, cLogP <5, cell viability IC50 >50µM) will be evaluated for
phenotypic effects (increases in H3K4me2) by immunofluorescent staining and
western blotting. Co-immunoprecipitation will also be performed to determine
whether the test compound promotes disruption of LSD1:CoREST:HDAC1/2.
Finally, we will evaluate in vivo toxicology of a 3,5-diamino-1,2,4-triazole
derivative using CD1 mice.

Specific Aim 3. Evaluate the pharmacodynamic efficacy of a lead 3,5diamino-1,2,4-triazole derivative to mitigate post-IR contractile dysfunction
and infarction using two murine models of IR. The purpose of this aim will be
to A) ascertain the protective effects of selected lead compounds identified in
Specific Aim 2 in reducing infarct and in improving contractile function, and B) to
establish LSD1 as an effective therapeutic target to abrogate IR damage. We will
use both an ex vivo isolated heart and an in vivo left anterior descending
coronary artery ligation-reperfusion model. Sprague-Dawley rats will be
	
  

42	
  

pretreated with each compound and their hearts will be isolated by Langendorff
preparation. After inducing transient global IR, left ventricular (LV) contractile
function and myocardial infarction will be observed. In addition, CD1 mice will be
evaluated 7-days post-IR surgery by echocardiography for functional analysis.

IX. SIGNIFICANCE
Treatment strategies for AMI continue to be palliative and methods for
reducing infarction following reperfusion have proven insufficient. Successful
completion of these aims will provide the first evidence that histone
demethylases play a significant role in pathological cardiac remodeling and
function. Notably, this result suggests a vast network of novel therapeutic targets
that have yet to be explored in CVD. To date, epigenetic targets in CVD primarily
focus on the vast array of HDACs and DNA methylation.51, 54 However, use of
insufficiently isoform-specific HDAC inhibitors results in a propensity for off-target
effects that can complicate mechanistic studies. Interestingly, recent evidence
shows a close cooperation between HDACs and LSD1.67 In addition, LSD1 itself
can produce oxidative stressors and damaging reactive aldehydes.81 Thus, we
will show a new innovative strategy to treat CVD through modulation of LSD1.
Transgenic studies with LSD1 have proven difficult because LSD1
knockdown is embryonic lethal.134 In addition, current LSD1 inhibitors are
undesirable for their overt toxicity or off-target efficacy. Therefore, we pursued to
successfully design and optimize a specific LSD1 inhibitor that could be used to
pinpoint LSD1 involvement in cardiac IR injury. More importantly, we strove to
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design a unique new chemotype that lacked the overt cytotoxicity seen with other
known LSD1 inhibitors. Herein, we will disclose highly potent small molecule
inhibitors of LSD1 that are the first published reversible, competitive inhibitors.133
In addition, all compounds show utility in the treatment of epigeneticallybased diseases where cell death is not a desired endpoint, such as CVD.
Completion of the specific aims for this study will provide a mechanistic
foundation for development of attractive cardiac drug candidates.
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CHAPTER 2: Materials and Experimental Methods
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I. CHEMISTRY REAGENTS AND REACTIONS
All reagents and dry solvents were purchased from Aldrich Chemical Co.
(Milwaukee, WI), Sigma Chemical Co. (St. Louis, MO), VWR (Radnor, PA) or
Fisher Scientific (Chicago, IL) and were used without further purification except
as noted below. Pyridine was dried by passing it through an aluminum oxide
column and then stored over KOH. Triethylamine was distilled from potassium
hydroxide and stored in a nitrogen atmosphere. Methanol was distilled from
magnesium and iodine under a nitrogen atmosphere and stored over molecular
sieves. Methylene chloride was distilled from phosphorus pentoxide and
chloroform was distilled from calcium sulfate. Tetrahydrofuran was purified by
distillation from sodium and benzophenone. Dimethyl formamide was dried by
distillation from anhydrous calcium sulfate and was stored under nitrogen.
Microwave procedures were carried out on a Biotage Initiator 8 microwave
synthesizer. Preparative scale chromatographic procedures were carried out on
a Teledyne Isco Combi-Flash Rf200 using silica gel 60 cartridges, 230-440
mesh. Thin layer chromatography was conducted on Merck precoated silica gel
60 F-254. Compound 9 was purchased from Ryan Scientific (Mt. Pleasant, SC)
and compounds 13-25 were purchased from Chembridge (San Diego, CA). TCP
was purchased from Acros Organics (Pittsburgh, PA).
All 1H- and 13C-NMR spectra were recorded on a Varian Mercury 400 mHz
spectrometer, and all chemical shifts are reported as d values referenced to TMS
or DSS. Splitting patterns are indicated as follows: s, singlet; d, doublet; t, triplet;
q, quartet; p, pentuplet; m, multiplet; br, broad peak. In all cases, 1H-NMR,
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C-

	
  
NMR and MS spectra were consistent with assigned structures. Mass spectra
were recorded by LC/MS on a Waters autopurification liquid chromatograph with
a model 3100 mass spectrometer detector. All target molecules 26-44 were
determined to be >95% pure by UPLC chromatography (95% H2O/5%
acetonitrile to 20% H2O/80% acetonitrile over 10 minutes) using a Waters
Acquity H-series ultrahigh-performance liquid chromatograph fitted with a C18
reversed-phase column (Acquity UPLC BEH C18 1.7 mM, 2.1 X 50 mm).

General procedure for the preparation of 2-chloro-6-phenoxy benzonitriles:
Synthesis of 2-chloro-6-phenoxybenzonitrile 23. To a 20 mL microwave
vial containing a magnetic stir bar was added 0.78 g (5.0 mmol) of 2-fluoro-6chlorobenzonitrile, 1.04 g (7.5 mmol) of K2CO3, 0.52 g (5.5mmol) of phenol and
12 mL of anhydrous DMSO. The vial was then sealed and stirred to distribute
the contents evenly. The mixture was then microwaved at 190oC for 6 min at
high absorption to insure even heating. The reaction mixture was then poured
into a beaker containing 100 mL of crushed ice to precipitate the product. The
aqueous layer was extracted with three 50 mL portions of diethyl ether, and the
ether layer was washed with 25 mL of saturated NaCl, dried over anhydrous
Na2SO4, filtered, and the ether was removed in vacuo to yield 1.11 g of the
desired diaryl ether 23 (97% yield). The crude product 23 was pure enough
(95%) to be used in the next reaction without further purification.

	
  

47	
  

	
  
General procedure for the preparation of 2-chloro-6-phenoxy benzylamines:
Synthesis of 2-chloro-6-phenoxybenzylamine 45. A 1.11 g portion of 44
(4.8 mmol) was dissolved in 50 mL of anhydrous diethyl ether, cooled to 0oC in
an ice bath and stirred while bubbling dry argon into the reaction mixture for 10
min. A 14.49 mL portion of 1.0 M LiAlH4 in THF (14.49 mmol) was then added
dropwise with stirring over 20 min. The resulting reaction mixture was allowed to
stir for 2hrs at 0oC, and then warmed to room temperature and allowed to stir
overnight. The mixture was cooled to 0oC, and the reaction was quenched by
the slow addition of Na2SO4•10 H2O. When the evolution of gas subsided, the
reaction was stirred for 30 min at room temperature, and the mixture was filtered
through a Celite pad. The filtrate was concentrated to dryness to yield crude 2chloro-6-benzoxybenzylamine 45.

General procedure for the preparation of target molecules 27-45:
Synthesis of N3-(2-chloro-6-phenoxybenzyl)-4H-1,2,4-triazole-3,5-diamine
9. A 0.935 g portion of benzylamine 45 (4.0 mmol) was dissolved in 12 mL of
diethyl ether and added to a 20 mL microwave vial equipped with a magnetic stir
bar. A 0.702 g portion of dimethyl cyanodithioiminocarbonate 46 (4.8 mmol) was
added and the vial was sealed. The contents were microwaved at 45oC for 5
min, cooled to room temperature, and the ether was removed in vacuo to yield
the intermediate 47 as a white to pale yellow solid.

A 0.192 g portion of

hydrazine hydrate (6.0 mmol) in 12 mL of dry ethanol was then injected, the vial
was stirred to break up the solid intermediate, and the resulting mixture was
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microwaved at 90oC for 10 min at high absorption. The ethanol was removed in
vacuo to yield crude 9, which was purified on silica (9% MeOH in CH2Cl2) to
afford 1.07 g of pure 9 (85%) as an off-white, amorphous solid.

1

H-NMR

(400MHz, CD3OD/TMS) δ 4.21 (s, 2H), 6.77-6.80 (dd, 1H), 6.99-7.01 (d, 2H),
7.11-7.15 (t, 1H), 7.20-7.27 (m, 2H), 7.33-7.38 (t, 2H). UPLC retention time: 12.1
min. MS calculated 315.09, found 316.33 ([M+1]+).

N3-(2-chloro-6-(4-(trifluoromethoxy)phenoxy)benzyl)-4H-1,2,4-triazole-3,5diamine 26. Compound 26 was synthesized exactly as described above in 86%
yield as a white solid. 1H-NMR (400MHz, CD3OD/TMS) δ 4.31 (s, 2H), 6.72 (s,
1H), 6.85-6.87 (dd, 2H), 7.04-7.08 (d, 1H), 7.26-7.33 (m, 2H), 7.49 (s, 1H). UPLC
retention time: 15.5 min. MS calculated 399.07, found 400.27 ([M+1]+).

N3-(2-chloro-6-(p-tolyloxy)benzyl)-4H-1,2,4-triazole-3,5-diamine 27. Compound
27 was synthesized exactly as described above in 82% yield as a white solid.1HNMR (400MHz, CD3OD/TMS) δ 2.17 (s, 3H), 4.39 (s, 2H), 6.71-6.78 (m, 3H),
7.19 (d, 1H), 7.37-7.45 (m, 2H). UPLC retention time 14.4 min. MS calculated
329.79, found 330.36 ([M+1]+).

N3-(2-chloro-6-(2-isopropyl-5-methylphenoxy)benzyl)-4H-1,2,4-triazole-3,5diamine 28. Compound 28 was synthesized exactly as described above in 78%
yield as a white solid. 1H-NMR (400MHz, CD3OD/TMS) δ 1.15-1.21 (d, 6H), 2.26
(s, 3H), 3.09-3.15 (m, 1H), 4.07 (s, 2H), 6.56-6.58 (dd, 1H), 6.97-7.00 (1H), 7.13	
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7.25 (m, 3H), 7.51 (s, 1H). UPLC retention time 16.0 min. MS calculated 371.15,
found 372.37 ([M+1]+).

N3-(2-chloro-6-(3-methoxyphenoxy)benzyl)-4H-1,2,4-triazole-3,5-diamine

29.

Compound 29 was synthesized exactly as described above in 81% yield as a
white solid. 1H-NMR (400MHz, CD3OD/TMS) δ 3.80 (s, 3H), 4.29 (s, 2H), 6.566.59 (dd, 1H), 6.60-6.61 (t, 1H), 6.72-6.75 (dd, 1H), 6.85-6.88 (dd, 1H), 7.25-7.32
(m, 3H). UPLC retention time 15.5 min. MS calculated 345.10, found 346.30
([M+1]+).

N3-(2-(4-(tert-butyl)phenoxy)-6-chlorobenzyl)-4H-1,2,4-triazole-3,5-diamine

30.

Compound 30 was synthesized exactly as described above in 81% yield as a
white solid.

1

H-NMR (400MHz, CD3OD/TMS) δ 1.35 (s, 9H), 4.02 (s, 2H), 6.78-

6.81 (dd, 1H), 6.95-6.98 (dt, 2H), 7.21-7.28 (m, 2H), 7.42-7.45 (dt, 2H). UPLC
retention time 16.1 min. MS calculated 371.15, found 372.37 ([M+1]+).

N3-(2-chloro-6-(3,5-dimethylphenoxy)benzyl)-4H-1,2,4-triazole-3,5-diamine

31.

Compound 31 was synthesized exactly as described above in 74% yield as a
white solid. 1H-NMR (400MHz, CD3OD/TMS) δ 2.30 (s, 6H), 4.41 (s, 2H), 6.64 (s,
2H), 6.81 (s, 2H), 7.21-7.29 (m, 2H). UPLC retention time 14.5 min. MS
calculated 343.82, found 344.33 ([M+1]+).
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N3-(2-(3,5-bis(trifluoromethyl)phenoxy)-6-chlorobenzyl)-4H-1,2,4-triazole-3,5diamine 32. Compound 32 was synthesized exactly as described above in 77%
yield as a white solid. 1H-NMR (400MHz, CD3OD/TMS) δ 4.01 (S, 2H), 7.14 (S,
1H), 7.25 (S, 2H), 7.33 (S, 1H), 7.49 (S, 1H), 7.57 (S, 1H). UPLC retention time
15.4 min. MS calculated 451.76, found 452.63 ([M+1]+).

N3-(2-chloro-6-(4-((trifluoromethyl)thio)phenoxy)benzyl)-4H-1,2,4-triazole-3,5diamine 33. Compound 33 was synthesized exactly as described above in 79%
yield as a white solid. 1H-NMR (400MHz, CD3OD/TMS) δ 4.22 (s, 2H), 7.14 (d,
1H), 7.28-7.39 (m, 5H), 7.40 (d, 1H). UPLC retention time 14.0 min. MS
calculated 415.05, found 416.24 ([M+1]+).

N3-(2-(4-bromo-2-(trifluoromethyl)phenoxy)-6-chlorobenzyl)-4H-1,2,4-triazole-3,5diamine 34. Compound 34 was synthesized exactly as described above in 61%
yield as a white solid. 1H-NMR (400MHz, CD3OD/TMS) δ 4.28 (s, 2H), 7.04 (d,
1H), 7.22 (d, 1H), 7.27 (dd, 1H), 7.44 (d, 1H), 7.55 (d, 1H), 7.71 (s, 1H). UPLC
retention time 15.4 min. MS calculated 460.99, found 462.18 ([M+1]+).

N3-(2-chloro-6-(4-((methyl)thio)phenoxy)benzyl)-4H-1,2,4-triazole-3,5-diamine 35.
1

H-NMR (400MHz, CD3OD/TMS) δ 2.32 (s, 3H), 4.07 (s, 2H), 7.14 (d, 1H), 7.31

(m, 2H), 7.39-7.47 (m, 2H), 7.55 (d, 1H). UPLC retention time 14.6 min. MS
calculated 361.08, found 362.23 ([M+1]+).
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N3-(2-chloro-6-(2-methoxy-4-methylphenoxy)benzyl)-4H-1,2,4-triazole-3,5diamine 36. Compound 36 was synthesized exactly as described above in 40%
yield as a white solid. 1H-NMR (400MHz, CD3OD/TMS) δ 2.40 (s, 3H), 3.75 (s,
3H), 6.54-6.57 (m, 3H), 6.83-6.88 (d, 1H), 7.06-7.18 (m, 2H). UPLC retention
time 14.7 min. MS calculated 359.11, found 360.29 ([M+1]+).

N3-(2-chloro-6-(3,5-dimethoxyphenoxy)benzyl)-4H-1,2,4-triazole-3,5-diamine 37.
Compound 37 was synthesized exactly as described above in 76% yield as a
white solid. 1H-NMR (400MHz, CD3OD/TMS) δ 3.75 (s, 6H), 6.14 (s, 1H), 6.22 (s,
2H), 6.90

(d, 1H), 7.26-7.33 (m, 2H). UPLC retention time 14.1 min. MS

calculated 375.11, found 376.29 ([M+1]+).

N3-(2-chloro-6-(2,3-dimethylphenoxy)benzyl)-4H-1,2,4-triazole-3,5-diamine

38.

Compound 38 was synthesized exactly as described above in 43% yield as a
white solid. 1H-NMR (400MHz, CD3OD/TMS) δ 2.14-2.21 (m, 3H), 2.35-2.37 (m,
3H), 6.52 (d, 1H), 6.73-6.79 (m, 3H), 7.01-7.20 (m, 2H).

UPLC retention time

15.0 min. MS calculated 343.12, found 344.33 ([M+1]+).

N3-(2-(benzo[d][1,3]dioxol-5-yloxy)-6-chlorobenzyl)-4H-1,2,4-triazole-3,5-diamine
39. Compound 39 was synthesized exactly as described above in 80% yield as a
white solid. 1H-NMR (400MHz, CD3OD/TMS) δ 4.41 (s, 2H), 5.51 (s, 2H), 6.00 (s,
1H), 6.99-7.11 (m, 3H), 7.33-7.39 (m, 2H).
calculated 359.08, found 360.25 ([M+1]+).
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UPLC retention time 13.7 min. MS

	
  

N3-(2-chloro-6-(phenylthio)benzyl)-4H-1,2,4-triazole-3,5-diamine 40. Compound
40 was synthesized exactly as described above in 91% yield as a white solid. 1HNMR (400MHz, CD3OD/TMS) δ 4.31 (s, 2H), 7.19 (m, 1H), 7.36-7.44 (m, 6H),
7.61 (d, 1H). UPLC retention time 14.2 min. MS calculated 331.07, found 332.28
([M+1]+).

N3-(2-chloro-6-((3,4-dimethoxyphenyl)thio)benzyl)-4H-1,2,4-triazole-3,5-diamine
41. Compound 41 was synthesized exactly as described above in 82% yield as a
white solid. 1H-NMR (400MHz, CD3OD/TMS) δ 3.67 (s, 6H), 4.40 (s, 2H), 6.56
(m, 2H), 7.04 (m, 2H), 7.39 (d, 1H), 7.49 (d, 1H). UPLC retention time 13.7 min.
MS calculated 391.09, found 392.29 ([M+1]+).

N3,N5-bis(2-methoxybenzyl)-1H-1,2,4-triazole-3,5-diamine
compound 10).

(commercial

Compound 10 was purchased from Chembridge (San Diego,

CA) as a white solid. 1H-NMR (400MHz, CD3OD/TMS) δ 3.64 (s, 6H), 4.17 (s,
2H), 6.86-6.90 (t, 2H), 6.94-6.96 (m, 4H), 7.21-7.27 (m, 2H). UPLC retention time
13.7 min. MS calculated 339.17, found 340.28 ([M+1]+).

II. IN VITRO DRUG CHARACTERIZATION AND ENZYME ASSAYS
Cell culture and reagents:
Calu-6

cells

(human

lung

adenocarcinoma

ATCC-HTB-56)

were

purchased from ATCC, and cultured in EMEM growth medium containing 10%
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(v/v) fetal bovine serum and 5% penicillin and streptomycin. Cultures were grown
at 37oC in a humidified environment containing 5% CO2. For each experiment,
cells were seeded at a starting density of 400,000 cells per T25 flask.

Determination of cell viability:
For

the

(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-

sulfophenyl)-2H-tetrazolium) (MTS) reduction assay, 4000 cells/well were seeded
in 100 µl medium in a 96‾well plate and the cells were allowed to attach at 37oC
in 5% CO2 for one day. The medium was aspirated and cells were treated with
100 µl of fresh medium containing appropriate concentrations of each test
compound. The cells were incubated for 4 days at 37°C in 5% CO2. After 4 days
20 µL of the MTS reagent solution (Promega CellTiter 96 Aqueous One Solution
Cell Proliferation Assay) was added to the medium. The cells were incubated for
another 2 hours at 37°C under 5% CO2 environment. Absorbance was measured
at 490 nm on a microplate reader equipped with SOFTmax PRO 4.0 software to
determine the cell viability. Cell counts were confirmed by counting DAPI stained
nuclei as previously mentioned.Absorbance was measured at 490 nm on a
microplate reader equipped with SOFTmax PRO 4.0 software to determine the
cell viability.

In vitro LSD1 demethylation assay and kinetics:
Inhibition assays and kinetics were performed using LSD1 Inhibitor
Screening Assay Kit (Cayman Chemical, #700120). The substrate and all
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compounds were incubated in assay buffer from 30 min up to 4 hr at 37°C as
described in the commercial protocol. The volume of each reaction well was 50
µl, containing 5 ml of a 200 mM solution of substrate peptide and 20 ml of a
15ng/ml enzyme solution. All compounds were diluted in 1% DMSO with assay
buffer to a final concentration of 50 mM. Fluorescence was measured at the
recommended wavelengths of λex=530 nm, λem-590 nm. IC50 determinations were
performed using serial dilutions at 10, 5, 2.5, 1.25. 0.625, 0.3125 and 0.156
mM)..

In silico molecular modeling:
LSD1 active site (PDB #3ZMT, LSD1-CoREST in complex with PRSFLV
peptide) was defined as a sphere enclosing residues within 10Å around the
crystallographic peptide ligand. Prior to energy minimization, LSD1 was
protonated and the PH was set to 7.4. The 3D structure of inhibitors was energy
minimized using MM94x force field for 1000 iterations and a convergence value
of 0.001 kcal/mol/Å as the termination criterion. Initial docking results yielded 60
poses of each structure bound the active site of LSD1. The top 5 poses that
yielded the lowest E-score were chosen for further analysis. The best fit for
binding was analyzed for interacting residues. Key interactions with compound 9
include two hydrogen bonds with aspartate 555 and another hydrogen bond with
the carbonyl of alanine 539. In addition, the compound participates in pi-stacking
with the flavin ring of the FAD cofactor within 2.98Å. Thus, compound 9 shows
close association with the active site and effectively prohibits substrate binding.
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Nanoisothermal calorimetry (ITC):
Experiment was performed on Nano-ITC Low Volume (TA Instruments).
Initial setup protocols were run with 55.6M H20/H20 titrations and run to remove
any background heat release upon injection. Using 50mM PBS, buffer was
added to the system with 20 injections to remove any buffer background.
Compound 9 was then diluted to 1µM with <1% DMSO, and injected into the
system to eliminate ligand background peaks. After equilibrating the system,
LSD1 was diluted to 500 nM, added to the cell, and titrated in with 10 injections
of compound 9.

Monoamine oxidase A and B activity assay:
MAO/A/B activity was measured with the luminescent MAO-Glo assay kit
(Promega, #V1452) according to the manufacturer’s instructions. In brief, total
MAO activity was assayed by incubation of compounds with MAO/A or MAO/B
enzyme solution containing MAO substrate according to the suppliers directions.
Reconstituted luciferin detection reagent was added, and the resulting
luminescent signal was detected with 0.5 integration time after 20 mins.

Immunofluorescence staining of global methylation:
Cells were seeded at 1x103 cells/well and were then stained for
Immunofluorescence (IF) imaging using fluorescently labeled secondary
antibodies. Cells were fixed and permeabalized as mentioned above, and then
blocked with 10% Normal Donkey Serum (NDS) for 1hr, washed with PBS, and
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incubated overnight at 4°C with the H3K4me2 antibody (Cell Signaling, #2139S).
Fluorescent secondary antibodies were added to corresponding wells at 1:500
dilutions in 1% NDS for 2 hours. Cells were washed, left in 1X PBS and imaged
using Hermes WiScan (IDEA Biomedical). The imaging system is able to view
10-40x pictures as well as quantify average intensity on a per-cell basis,
eliminating any bias towards IF staining. Quantification of H3K4me2 marks was
presented as a frequency distribution of the cell count population.

Cell viability/Cytotoxicity assay:
For

the

(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-

sulfophenyl)-2H-tetrazolium) (MTS) reduction assay, 3x103 cells/well were
seeded in 100µl medium in a 96-well plate and allowed to attach at 37°C in 5%
CO2 for one day. The medium was aspirated and cells were treated with 100µl of
fresh medium containing appropriate dose-response concentrations of each test
compound. The cells were incubated from 48-72hrs at 37°C in 5% CO2. After,
20µL of the MTS reagent solution (Promega CellTiter 96 Aqueous One Solution
Cell Proliferation Assay) was added to the medium. The cells were incubated for
another 2 hours at 37°C. Absorbance was measured at 490 nm on a microplate
reader equipped with SOFTmax PRO 4.0 software to determine the cell viability.
Cell counts were confirmed by counting DAPI stained nuclei as previously
mentioned.
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Preparation of cell lysates:
Following treatment, cells were washed twice in sterile filtered cold 1×
PBS. Cells were then lysed in 200 µl of lysis buffer (20 mM Tris, 150 mM NaCl, 1
mM EDTA, 1 mM EGTA, 1 mM β-glycerol, 2.5 mM sodium pyrophosphate, and
1% Triton X-100) Protease and phosphatase inhibitors were added to these
buffers (1:100 dilutions of phosphatase inhibitor cocktail I and II and protease
inhibitor cocktail; Sigma). The cells were then incubated on ice for 15 min, and
insoluble material was pelleted by centrifugation at 4°C.

Western blot analysis:
Protein concentrations were determined by Pierce BCA protein assay kit
(Thermo Sci, Product #23225). Cell lysates were subjected to SDS-PAGE, and
Western blot analysis was performed with the appropriate antibodies. Primary
antibodies against H3K4me2, H3K4me1, LSD1, GAPDH, p-p38, p-Akt and
catalase were from Cell Signaling; Histone H3 primary antibody was from
Millipore. Proteins were visualized by enhanced chemiluminescence (ECL).

Primary rat cardiomyocytes isolation:
Primary male Sprague-Dawley rat cardiomyocytes were isolated via a
hanging heart preparation using enzymatic digestion, as previously described.135136

In brief, rats were euthanized with 5% isoflurane vaporized in 100% O2. The

heart was retrogradely perfused with collagenase. The cardiomyocytes were
plated on 6-well culture trays that were coated with laminin at an initial plating
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density of 1.5 × 105 cells/well. After overnight incubation, the cardiomyocytes
were rinsed and maintained in serum-free medium.

Co-immunoprecipitation:
Primary rat cardiomyocytes were isolated as described earlier and treated
with varying concentrations of test compounds. Cells were lysed and scraped
with IP Lysis Buffer (20mM Tris-Cl, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1mM
β-glycerol, 2.5mM Na pyrophosphate). Dynabeads (Life Biosciences) were
added 1:10 beads:lysate (v/v) and incubated at 4°C for 1-hour to pre-clear.
Mixture was centrifuged (5000rpm) and the supernatant was saved. An antibody
(2-5 µg) for the protein of interest was added and rocked overnight in cold room.
Dynabeads (20 µL) were added and incubated at room temp for 1-hour.
Centrifuge mixture for 1-minute at 5000rpm. The supernatant was decanted and
the pellet washed 3X with IP Lysis Buffer with 0.1% Triton X-100. Samples were
then analyzed by SDS-PAGE and immunoblotted.

III. PRECLINICAL TESTING – EX VIVO AND IN VIVO MODELS
Langendorff ex vivo retrograde perfusion isolated hanging heart model:
Male Sprague-Dawley rats (250-300g) were pretreated with test
compound at an appropriate dosage determined from Specific Aim 2.

For

reference, in vivo literature on triazole compounds indicates 10mg/kg, i.p.,
QD21,23 Hearts were isolated by Langendorff preparation (Figure 2.1). Rats were
anesthetized with ketamine/xylazine (85/15mg/kg, i.p.). The trachea was
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cannulated with a 16-guage angiocatheter attached to a rodent ventilator. A
midsternal thoracotomy was then performed to remove the heart. The aorta was
cannulated in situ and perfused at a constant 75mmHg using Krebs-Henseleit
buffer (1.25mM CaCl2, 11mM glucose, 112mM NaCl, 25mM NaHCO3, 5mM KCl,
1.2mM MgSO4, 1mM K2PO4, and 0.2mM octanoic acid, bubbled with 95%
O2/5% CO2, pH 7.4). Hearts were then perfused with buffer for 15min prior to
30-mins of global ischemia. Reperfusion was induced for 60min. A saline-filled
balloon fixed to a pressure transducer inflated to 5-10mmHg in the LV measured
contractile function. Pain and suffering was minimized in these models via use of
anesthesia and analgesia. Anesthetic depth was monitored by loss of blink reflex
and loss of response to pain by toe-pinch.
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Figure	
   2.1.	
   Langendorff	
   ex	
   vivo	
   isolated	
   heart	
   retrograde	
   perfusion	
  
apparatus.	
   Male	
   Sprague-‐Dawley	
   rats	
   were	
   cared	
   for	
   in	
   accordance	
   to	
   the	
  
guidelines	
   of	
   the	
   Institutional	
   Animal	
   Care	
   and	
   Use	
   Committee.	
   They	
   were	
  
anesthetized	
  with	
   (in	
   mg	
   per	
  kg)	
  85	
   ketamine/15	
  xylazine.	
  Tracheal	
  ventilation	
  
was	
   followed	
   by	
   translateral	
   thoracotomy	
   to	
   expose	
   the	
   aorta,	
   which	
   will	
   be	
  
cannulated	
   in	
   situ.	
   The	
   heart	
   was	
   rapidly	
   excised	
   to	
   external	
   perfusion	
   with	
  
modified	
   Krebs-‐Henseleit	
  buffer	
  heated	
   to	
   37.4	
   °C	
  and	
   bubbled	
   with	
  (in	
   %)	
   95/5	
  
oxygen/carbon	
  dioxide.	
  Coronary	
  flow	
  was	
  measured	
  using	
  a	
  Doppler-‐type	
  flow	
  
meter	
   (Transonic	
   Systems	
   Inc.,	
   Ithaca,	
   NY)	
   and	
   left	
   ventricular	
   contractile	
  
function	
   was	
   monitored	
   via	
   insertion	
   of	
   a	
   saline-‐filled	
   balloon	
   connected	
   to	
   a	
  
pressure	
   transducer	
   (AD	
   Instruments,	
   Colorado	
   Springs,	
   CO).	
   Hearts	
   were	
  
perfused	
   with	
   buffer	
   for	
   15	
   min	
   before	
   induction	
   of	
   global	
   ischemia	
   through	
  
complete	
   cessation	
   of	
  perfusion	
   for	
   30	
   min.	
   Reperfusion	
   was	
   then	
   induced	
   for	
   60	
  
min	
   through	
   restoration	
   of	
   normal	
   perfusion	
   with	
   oxygenated	
   buffer	
   at	
   75	
   mm	
  
Hg	
  perfusion	
  pressure.	
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Infarct area staining by 2,3,5-triphenyltetrazolium chloride (TTC):
After Langendorff preparation, hearts were frozen at -80°C. A transverse
sectioned into 2-mm slices was performed and incubated in 1% 2,3,5triphenyltetrazolium chloride (TTC) at 37 °C for 10 min. Quantification of infarct
area will be performed using ImageJ software (National Institutes of Health, USA,
http://imagej.nih.gov/ij). Infarct size was reported as a percent of the total left
ventricular area.

Left anterior descending coronary ligation-reperfusion in vivo IR:
Male CD1 mice (25-35g) underwent in vivo left anterior descending (LAD)
coronary artery ligation-reperfusion as previously performed and described.137 In
short, the LAD was ligated with 6-0 silk suture and PE-10 tubing for 40-min prior
to reperfusion. Compound 9 (3 mg/kg) or GSK-LSD1 (0.5 mg/kg) was injected
intraperitoneal immediately following ligation and again once daily for 7-days.
Echiocardiographic determinations of LV volumes and ejection fractions was
performed with a 15-MHz transducer (Sonos 5500; Agilent Technologies,
Andover, MA, USA) placed on the hemithorax. Briefly, the parasternal long-axis
view of the LV was recorded. LV volumes were determined by planimetry of the
LV endocardial border at end diastole (frame with R wave) and end systole
(smallest LV area in the cardiac cycle) and application of a variant of Simpson’s
algorithm (i.e. “method of disks”). The thoracic area was shaved and the heart
removed via a midline sternotomy. Euthanasia occured via exsanguination. All
animals were placed under full surgical anesthesia for heart harvesting. Mice
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were cared for in accordance to the guidelines of the Institutional Animal Care
and Use Committee. Male CD1 mice were anesthesized by 3% isoflurane
vaporized in 100% O2. The experiment was repeated using the positive control,
GSK-LSD1 (0.5 mg/kg, i.p.).

IV. DATA ANALYSIS AND STATISTICS. Power analyses was performed using
a one-way analysis of variance model to determine sample size for each
experiment in this application. All data was presented as mean ± SEM.
Significant differences within group comparison between baseline and terminal
studies in any parameter were tested using unpaired t-test corrected for multiple
comparisons using the Bonferroni method. Unless stated otherwise, α = 0.05 and
β = 0.80. The sample sizes for each experiment was listed under individual figure
legends.

V. ETHICAL ASPECTS OF RESEARCH AND ANIMAL CARE
The ethical aspects of this research are limited to animal models. All of the
animal work performed for this research was performed under approved animal
protocols at the Medical University of South Carolina and the Ralph H. Johnson
VA Medical Center. All experimental protocols conformed to the Guide for the
Care and Use of Laboratory Animals published by the US NIH.
Rats were housed and cared for by the Division of Laboratory Animal
Resources under the direction of Alison C. Smith, D.V.M., a diplomate of
ACLAM. An assurance statement is on file with OPRR/DHHS detailing the
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program for animal care at this institution, which has full accreditation from
AAALAC effective 11/5/87. Trained AALAS-certified technicians cared and fed
the animals including monitoring the health of animals on a routine basis. Several
veterinarian consultants were available for animal care. All procedures involving
rats were done in accordance with the NIH Guide for the Care and Use of
Laboratory Animals.
Pain and suffering was minimized in these models via use of anesthesia
and analgesia. Rats were anesthetized via ketamine/ xylazine (85/15 mg/kg).
Anesthetic depth was monitored by loss of blink reflex and loss of response to
pain by toe-pinch. The thoracic area was shaved and the heart removed via a
midline sternotomy. Euthanasia occured via exsanguination. All animals were
placed under full surgical anesthesia for heart harvesting.
All rats were humanely euthanized in accordance with accepted IACUC
protocol. Euthanasia was accomplished via exsanguination following removal of
the heart. This procedure was performed under full surgical anesthesia. This
method is consistent with the recommendations of the American Veterinary
Medical Association Guidelines on Euthanasia.
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CHAPTER 3: Structure-based discovery of small molecule LSD1 inhibitors
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I. INTRODUCTION
To

date,

effective

LSD1

inhibitors

include

tranylcypromine-based

analogues138-141 such as 2, oligoamines such as verlindamycin 5,142 related
isosteric ureas and thioureas,143-144 and peptide based LSD1 inhibitors such as
6.145-146 However, it is the tranylcypromine related analogues that have garnered
the most attention. The tranylcypromine scaffolds are the most advanced
chemical class with respect to drug development, and the first clinical trial for a
tranylcypromine-based LSD1 inhibitor for treatment of acute myeloid leukemia
began earlier this year.147 TCP is a moderately potent, irreversible inhibitor of
LSD1. However, it is challenging to design a TCP-based LSD1 inhibitor for
clinical use that is specific, has low toxicity, and is devoid of the many biological
responses to TCP itself. Thus, these analogues have the potential to produce offtarget

effects

mediated

through other

flavin-dependent

amine

oxidase

enzymes.148 In addition, covalent compounds, such as these, are less desirable
as clinical therapeutics than reversible ones. As such, there is a continuing need
to identify novel small-molecule scaffolds for inhibitors of LSD1 that can be used
to design highly specific, reversible LSD1 inhibitors. This chapter focuses on de
novo identification, screening, synthesis, and in vitro characterization of novel
small molecule LSD1 inhibitors. Herein, we describe a novel scaffold for a new
series of reversible, competitive inhibitors of LSD1 using a 3,5-diamino-1,2,4triazole scaffold.
Potential new scaffolds for small molecule LSD1 inhibitors were identified
through a virtual screen of the Maybridge Hitfinder 5 compound library. This
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virtual library consists of 50,000 compounds with high chemical diversity for rapid
lead identification. Based on the lowest energy conformers to the crystal
structure of LSD1/CoREST (PDB 2V1D), we were able to identify 10 potential
leads. From this short list, we selected our initial parent compound based on
chemical moieties and ease of synthesis.

After screening 15-analogous

compounds for LSD1 inhibition at 10 µM, we selected compounds 9 and 10 for
further evaluation. In addition, a synthesis for a small chemical library of 3,5diamino-1,2,4-triazolamine structures was performed by an aminolysis of
dimethyl-N-cyanodithiocarbonimidate followed by cyclization of the obtained Ncyano-S-methylisothiourea with hydrazine.
The results in this chapter disclose	
   one of the first small molecule,
reversible, competitive LSD1 inhibitors that is active at low micromolar
concentrations.

Therefore,

the

compounds

covered

show

significant

characteristics desirable as clinical therapeutics. Figure 3.1 shows a workflow
diagram of results covered in this chapter.

Goals of Chapter 3:
1.) Perform computational, structure-based virtual screen to
identify high affinity ligands
2.) High-throughput screening for lead identification
3.) Synthesis of small, focused chemical library
4.) Evaluate in vitro efficacy against LSD1
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Figure 3.1. Chapter 3 workflow chart and structure-based drug design of
novel LSD1 inhibitors. Early de novo drug design from a virtual screen to
drug synthesis to lead optimization.
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II. RESULTS
Virtual screen for novel LSD1 inhibitors:
Potential new scaffolds for small-molecule LSD1 inhibitors were identified
through a virtual screen of the Maybridge Hitfinder 5 compound library, as
previously described. The crystal structure of LSD1/CoREST (PDB 2V1D) was
prepared using PrepWizard, and SiteMap was then used to assess efficient
binding within the LSD1 histone-binding pocket (Figure 3.2). The active site
features a hydrophilic pocket near an FAD cofactor, with a large hydrophobic
region nearby. Lowest energy conformers of 3D compounds were determined
and docked in the LSD1 active site using Glide. A total of 10 hits were identified
with Glide scores lower than -7.5 kcal/mol (compounds not shown). The
synthesis and biological evaluation of other lead compounds identified in this
screen have been previously published.149 The 3,5-diamino-1,2,4-triazole 9 was
chosen as a potential high affinity ligand for LSD1 efficacy because it featured an
appropriately positioned hydrophobic aromatic ring and significant H-bonding
donors and acceptors within the triazole ring.
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A.

B.

Figure 3.2. Virtual screen of Maybridge HitFinder library against
LSD1/CoREST	
   (PDB 2V1D). (A) Maybridge HitFinder was used because
their virtual library contains a very high percentage of “druggable”
compounds that conform to Lipinski’s guidelines for successful therapeutic
agents. (B) The LSD1 active site (green) contains a large hydrophobic
pocket (dotted yellow) in close proximity to the FAD cofactor (red).	
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In silico molecular docking and predicted catalytic binding affinity:
Compounds that bind in close proximity to the FAD cofactor within the
active site of LSD1 typically show greater potency towards the enzyme.
Therefore, in silico molecular modeling (GOLD software package, version 5.1,
Cambridge Crystollagraphic Data Center, Cambridge, UK) was performed to
predict key residues interacting with 9 (Figure 3.3) and 10 (data not shown). The
LSD1 active site (PDB #3ZMT, LSD1-CoREST in complex with a peptide with the
sequence PRSFLV) was defined as a sphere enclosing residues within 10Å
around the bound peptide ligand. Prior to energy minimization, protein residuess
were protonated and the pH was adjusted to 7.4. Initial screens focused on using
the PRSFLV peptide for defining potential key interaction sites. The 3D inhibitor
structures were energy minimized using the MM94x force field using 1000
iterations and a convergence value of 0.001 kcal/mol/Å as the termination
criteria. Initial docking results yielded 60 poses of each structure bound in the
active site of LSD1. The top 5 poses that yielded the lowest E-score were chosen
for further analysis. The best fit for binding was analyzed for interacting residues.
Key interactions with 9 include two hydrogen bonds with aspartate 555 and
another hydrogen bond with the carbonyl of alanine 539.

In addition, the

compound participates in pi-stacking with the flavin ring of the FAD cofactor
within 2.98Å. Thus, 9 shows close association with the active site and effectively
prohibits substrate binding.

A 2-dimensional rendition of the binding of 9 to

LSD1/CoREST is also shown in Figure 3.3.
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Figure 3.3. Molecular docking of compound 9. In silico analysis in the
LSD1/CoREST catalytic site (PDB file 3ZMT). The aromatic portion of the
o-phenoxy substituent lies 2.98Å from the FAD cofactor.
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In vitro activity against recombinant LSD1/CoREST:
In the present study, one hit from the virtual screen, 9, was identified, and
this compound, as well as related analogues 10 and 13-25, were purchased and
evaluated (Table 3.1).	
   The ability of compounds 9-25 to inhibit purified
recombinant LSD1 was measured using a commercially available fluorescencebased assay kit (Cayman Chemicals #700120). Initially, all compounds were
tested at a concentration of 10 µM in phosphate-buffered saline (PBS) containing
<1% DMSO (Figure 3.4A). The screen was performed as suggested by the
supplier and modified as previously described.143, 149 Compounds 9 and 10 were
the most effective inhibitors of LSD1 (%LSD1 activity remaining 15.1 ± 4.7 and
25.1 ± 1.9, respectively). For comparison, tranylcypromine (2) and 5 reduced
LSD1 activity to 72.6 and 15.8%, respectively. Compounds 9 and 10 were then
subjected to titration analysis to determine the in vitro IC50 of each compound
against LSD1 (Figure 3.4 B and C). Compound 9 possessed an IC50 value of
1.19 µM while compound 10 had an IC50 value of 2.22 µM.
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Synthesis of 3,5- diaminotriazole analogues:
In order to produce additional analogues in the 3,5-diaminotriazole library,
a synthesis of 9 was developed as shown in Scheme 1. Condensation of phenol
42 and 2-cyano-3-chlorofluorobenzene 43 (K2CO3, microwave, 190oC, 6 min)
resulted in the phenoxyphenyl intermediate 44. The cyano group in compound 44
was then reduced (LiALH4) to afford primary amine 45, which was reacted with
46 (microwave, 40oC, 5 min) to yield 47. Intermediate 48 was then treated with
hydrazine (microwave, 90oC, 10 min) to produce the desired 3,5-diaminotriazole
9. This route was used to synthesize the previously unreported 3,5diaminotriazoles of general structure 1, compounds 26-41 (Table 3.2). Each
compound was evaluated as an inhibitor of recombinant LSD1 as described
above at a concentration of 10 µM (Figure 3.5). Seven compounds (9, 10, 31,
34, 36, 37 and 38) were more effective LSD1 inhibitors at 10 µM than the known
LSD1 inhibitor 5, while 11 of the 16 compounds measured inhibited LSD1 by
50% or more. Compounds 36 and 38, which have LSD1 inhibitory activity
comparable to 9, demonstrate additional functional groups that will drive future
chemical manipulation (see “IV. Limitations and Future Directions”).
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Table 3.1. Structures, cLogP and LSD1 inhibitory activity for 3,5diaminotriazoles 9-25. Activity mean ± SEM (n=3)
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Table 3.1 (continued). Structures, cLogP and LSD1 inhibitory activity for
3,5-diaminotriazoles 9-25. Activity mean ± SEM (n=3)
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A.

	
  

	
  

B.

	
  
	
  

C.

	
  	
  

Figure 3.4. Initial LSD1 inhibition assay. (A) Percent LSD1 activity
remaining after 10 µM treatment with 3,5-diamino-1,2,4-triazolamine 9 and
chemically similar 10-25. Positive control compounds verlindamycin, 5, and
tranylcypromine, 2, showed similar inhibition at 10 µM as previously described.
Dose-response of LSD1 following treatment with compounds 9 (B) and 10 (C).
Compound 9 IC50 = 1.19 µM; compound 10 IC50 = 2.22 µM.
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Table.	
  3.2.	
  Structures	
  and	
  LSD1	
  activity	
  of	
  compounds	
  from	
  Scheme	
  1	
  

	
  
Figure 3.5. LSD1 inhibition assay of synthesized compounds. Residual
LSD1 activity remaining after treatment with 3,5-diamino-1,2,4-triazoles
derivatives 6, 10, 26-41 at 10 µM. Positive control compounds
verlindamycin, 5, and tranylcypromine, 2. Each data point is the average of
3 determinations ± SEM (see above Table 3.2).	
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Compound 9 is a reversible, competitive inhibitor of LSD1
The fluorescence-based assay method described above was then used to
determine Michaelis-Menten kinetics for 9, as shown in Figure 3.6A. In brief,
compound 9 was incubated at 0, 0.375, 0.75 and 1.0 µM for 30 mins with 15
ng/µL of LSD1 at 37OC prior to addition of increasing amounts of the H3K4me2
peptide substrate (concentrations between 0 and 100 µM). Initial rates were
determined by linear least-squares fit, and Km and Vmax values were determined
using the GraphPad Prism 6 software package. The Vmax remained constant
(30.62 ± 0.8 unit/min) indicating competitive inhibition, and the Ki for 9 was
determined to be 2.20 µM (Figure 3.6B).
To assure that 3,5-diaminotriazoles were bound to LSD1 with 1:1
stoichiometry, nanoisothermal titration calorimetry (TA Instruments Nano ITC)
was performed (Figure 3.7) using 9 and purified LSD1 (Enzo Life Sciences,
#BML-SE544-0050). The isotherm was generated by titrating 2 µL injections of a
1 µM solution of 9 into a 500 nM solution of recombinant LSD1 at 25oC. Titration
of 9 to LSD1 resulted in an independent binding isotherm signifying significant
heat release on binding of 9 to LSD1. The R2 of heat released and the molar
ratio was found to be 0.96. The resulting isotherm clearly shows that 9 and LSD1
bind with a 1:1 stoichiometry with a Ka = 48.89 nM-1 and 0.02nM Kd (calculated
by the ITC system software).
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A.

B.	
  	
  
	
  

	
  

Figure 3.6. LSD1 enzyme kinetics show compound 9 as a
competitive inhibitors. A fluorometric assay was used to evaluate
kinetics. (A) Competitive enzyme inhibition kinetics for LSD1 treated
with compound 9 at 0, 0.375, 0.75, and 1µM concentrations over a
range of substrate concentrations between 0 and 100 mM; Ki for 9 = 2.2
µM. (B) Table showing the values of Vmax and Km for enzyme kinetics.
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Figure 3.7. Thermal biomolecular binding of compound 9 to
LSD1. Isothermal calorimetry (ITC) was performed using a
Nano-ITC (TA Instruments). The thermal trace for LSD1 showed
a exothermic release of heat upon titration with compound 9.
Ka = 48.89 nM, R2=0.96.
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III. DISCUSSION
Newly identified roles for epigenetic modulation mediated by LSD1
continue to emerge, both in cancer and in other disease states. Thus, LSD1 has
become a promising target for therapeutic intervention. While the design of
irreversible LSD1 inhibitors has been fundamental in the biological evaluation of
LSD1, reversible inhibitor development has been less successful. The
tranylcypromine-based irreversible inhibitors are the most advanced chemical
class with respect to drug development and many successful LSD1 inhibitors are
derived from tranylcypromine scaffolds. However, these irreversible inhibitors all
require activation and/or covalent attachment to the FAD cofactor for inhibition of
LSD1. Therefore, it is challenging to design selective LSD1 inhibitors that do not
show off-target effects mediated through	
   other flavin-dependent enzymes.148 As
such, there is a continuing need to identify novel small-molecule scaffolds for
inhibitors of LSD1 that can be used to design highly specific LSD1 inhibitors. The
3,5-diamino-1,2,4-triazole motif described in this chapter could be used as such a
scaffold, and the results described above support the contention that potent, nontoxic LSD1-specific inhibitors can be designed in this chemical class.
We successfully identified a new 3,5-diamino-1,2,4-triazole scaffold using
computational chemistry. A virtual screen was performed with the Maybridge
HitFinder 50,000 compound library, which revealed structurally distinct drug-like
compounds as potential leads. Interestingly, compounds with primary amines,
hydrophobic electron withdrawing groups, and heterycycloalkyl groups were well
represented in our computational analysis. Of the 10 identified through selection
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criteria discussed earlier, 1 compound (and 14 chemically similar compounds)
were procured and screened in a recombinant LSD1/CoREST biochemical
assay. Two novel compounds, 9 and 10, were active with IC50(LSD1) <2 µM. The
docking interactions of 9 include two hydrogen bonds with aspartate 555 and
another hydrogen bond with the carbonyl of alanine 539.

In addition, the

compound participates in pi-stacking with the flavin ring of the FAD cofactor
within 2.98Å (Figure 3.3). Thus, 9 shows close association with the active site
and effectively prohibits substrate binding.
isothermal calorimetry.

This binding was confirmed by

We then used enzyme kinetics to investigate the

mechanism of action of compound 9 inhibition. Our calculated Km = 53.4 ± 7 µM
of the peptide was significantly higher than previously reported for a 21-mer
H3K4me2 synthetic peptide. This may be attributed to the higher salt content in
our reaction buffer, which is known to decrease affinity of the histone tail.150
A synthetic route to produce analogues of 9 was developed, as shown in
Scheme 1. Each newly synthesized compound was evaluated as an inhibitor of
recombinant LSD1/CoREST as described above at a concentration of 10 µM
(Figure 3.5). Six compounds (9, 10, 31, 34, 36 and 38) were more effective
LSD1 inhibitors than the known LSD1 inhibitor 5, while 11 of the 16 compounds
measured inhibited LSD1 by 50% or more. Therefore, these results indicate a
limited chemical library of 9 derivatives can be synthesized that is expected to
contain multiple active compounds. We are continuing to synthesize analogues
in this series for the purpose of refining a structure/activity model for 3,5-diamino1,2,4-triazole-based LSD1 inhibitors.
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IV. LIMITATIONS AND FUTURE DIRECTIONS
The LSD1 inhibitor screening assay is a fluorescence-based method for
determining enzyme activity. During the first oxidative phase of demethylation,
the reduced cofactor FAD reoxidizes to its functional form by molecular oxygen
and releases H2O2 as a byproduct.

The H2O2 reacts with 10-acetyl-3,7-

dihydroxyphenoxazine (Amplex Red) to produce the highly fluorescent
compound resorufin (Cayman Chemical, #700120). Therefore, our readout is an
indirect measure of enzyme activity and may create variability in drug screens.
An in vitro antibody-based assay with bulk histones and recombinant LSD1 can
be used as an alternative, as previously described.151-152

In addition, kinetic

Isothermal Titration Calorimetry (kinITC) can be used to obtain kinetics
information, as well as kon and koff for experimental compounds.153
Recently, using a similar synthesis to Scheme 1, we synthesized a series
of new compounds with unique hydrophobic electron withdrawing groups. Two
regioisomer derivatives, M1 and M2, contain naphthalene-substituted phenols,
and show very low nanomolar range IC50 values for recombinant LSD1/CoREST
(Figure 3.8). Thus, further biochemical evaluation of these highly potent LSD1
inhibitors is warranted.

In addition, analogues containing functional groups

designed to increase aqueous solubility are being synthesized.
Finally, a synthesis to generate compound 10 derivatives is also being
generated, utilizing azide-alkyne cycloaddition click chemistry. Appropriate
acetylenes and azides can be readily coupled using click chemistry in a single
step (Scheme 2). Points for the introduction of chemically diverse substituents
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where Z, R1 and R2 are any halogen, electron withdrawing group, alkyl group,
aralkyl group, heteroalkyl or other substitution, and X and Z are carbon or
heteroatoms such as S, N, O.

	
  	
  	
  

	
  

Figure 3.8. Lead optimization of compound 9 derivatives unveil novel
compounds with improved potency. IC50 values of new compounds show
M1 (123 nM) and M2 (99 nM). Data credited to Mark Johnson, PhD.

Scheme 2.
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Chapter 4: Assessment of selectivity, toxicity, and target validation of 3,5diamino-1,2,4-triazoles.

	
  

87	
  

I. INTRODUCTION
The amine oxidase family shows close sequence homology within their
active sites and their catalytic mechanism. For this reason, selective inhibition of
individual amine oxidases remains difficult. Many of the most successful
inhibitors within the family show efficacy for other members and have been
utilized as scaffolds for drug development. For instance, the most abundant class
of effective LSD1 inhibitors is structurally based a nonspecific MAO inhibitor.154
Therefore, this increases the potential for off-target effects mediated by other
amine oxidases.

More importantly, LSD1 inhibitors are being developed as

antitumor agents, with the intent of cancer cell cytotoxicity. Because LSD1
biological function is better characterized within carcinogenesis and metastasis,
the need for explicit toxic drugs has been a main focus in currently available
compounds. In recent years, this paradigm has shifted with the emerging role of
LSD1 in diseases other than cancer

155-159

, and as such, there is a need for

potent epigenetic modulators that do not cause overt cytotoxicity.
Many LSD1 inhibitors show poor selectivity and in vivo toxicity, making it
difficult to study the effects of specifically inhibiting LSD1.154 Of the most potent
and selective LSD1 inhibitors identified, the majority are based on the clinically
used

antidepressant

tranylcypromine

and

were

designed

as

cancer

chemotoxicants.160 Unfortunately, many tranylcypromine-based LSD1 inhibitors
rely on covalent, irreversible adduct formation with FAD to inactivate the enzyme.
For these reasons, current LSD1 inhibitors are undesirable as drug candidates
for cardiovascular disease, where overt cytotoxicity and cell death is not a
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desired endpoint.

Thus, we have decided to pursue a new chemotype of

reversible LSD1 inhibitors with increased potency, higher specificity, and reduced
toxicity that are attractive drug candidates for cardiovascular disease.
This chapter focuses on the in vitro characterization of newly synthesized
3,5-diamino-1,2,4-triazole, 9 and 10, for LSD1 selectivity, cellular cytotoxicity,
and biological efficacy. First, the two lead compounds were screened against
MAO-A, MAO-B, and spermine oxidase. Both 9 and 10 showed a selectivity
index >100 for MAO-A and MAO-B. However, both 3,5-diamino-1,2,4-triazole
derivatives showed significant potency for recombinant spermine oxidase (IC50 =
40-150 nM).

Therefore, in our future cardiovascular studies using these

compounds, we needed to dissect the individual roles of LSD1 and SMO. Thus,
we screened a current SMO inhibitor, MDL 72527 (11), and a recent
commercially available LSD1 inhibitor (3), for potency against both enzymes.
Secondly, we screened our lead compounds for cytotoxicity in various cell lines
and in vivo administration. In particular, we found that both 9 and 10 showed
limited toxicity.

Finally, both compounds were evaluated for their ability to

increase histone methylation of H3K4, a known substrate of LSD1, and disrupt
the LSD1/CoREST/HDAC corepressor complex in primary rat cardiomyocytes.
Figure 4.1 shows a workflow diagram of results covered in this chapter.
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Figure 4.1. Chapter 4 workflow chart and in vitro characterization of
two lead LSD1 inhibitors, 9 and 10. LSD1 selectivity, cytotoxicity, and
biological efficacy will be evaluated.
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GOALS FOR CHAPTER 4:
1.) Determine MAO-A, MAO-B, and SMO IC50 for both
lead compounds
2.) Screen compounds 9 and 10 in six different cell lines
and quantify toxicity IC50
3.) Demonstrate compounds enter the cell and increase
LSD1 substrate (H3K4me2)
4.) Show disruption of LSD1:CoREST:HDAC corepressor
complex by inhibition of LSD1 in cardiomyocytes
5.) Perform an in vivo toxicology screen

II. RESULTS
Selectivity of 3,5-diaminotriazoles – Monoamine Oxidases:
LSD1 and other amine oxidases, such as the monoamine oxidases
(MAO), use the cofactor FAD to reoxidize molecular oxygen to produce H2O2.
Tranylcypromine and derivatives often show significant off-target efficacy against
MAO-A and MAO-B, and thus, are undesireable as clinical compounds.
Therefore, it is crucial in the design of new LSD1 inhibitors to screen for efficacy
against MAO-A and MAO-B. A commercial recombinant luminescent assay
(Promega

Corporation,

#V1401)

was

performed

as

described

by

the

manufacturer to assess the ability of 3,5-diaminotriazole 9 and 10 to inhibit MAO
A and B isoforms. In short, Compounds 9 and 10 were titrated in 1% DMSO and
incubated with MAO enzyme with a luminogenic MAO substrate and MAO-GloTM
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reagent.

MAO activity converts MAO-GloTM to luciferin, which reacts with

luciferase, and can be quantified by spectrophotometer. The amount of light
produced is directly proportional to MAO activity. Compounds 9 and 10 both
exhibited IC50 values greater than 100 µM against both MAO isoforms, while
tranylcypromine inhibited MAO A and B with IC50 values of 4.2 µM and 5.8 µM,
respectively (Figure 4.2).
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A.

B.

Figure 4.2. Monoamine oxidase A and B activity. MAO A and MAO
B enzyme activity for 3,5-diaminotriazoles 9 and 10 compared to the
known MAO inhibitor tranylcypromine (TCP). TCP IC50= 4.2 µM and 5.8
µM for MAO A and MAO B, respectively). Compounds 9 and 10
exhibited IC50 values > 100µM for both MAO A and B. Graphs are
representative of 3 separate experiments, with n=4-6 wells per
treatment. Mean ± SEM.
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Selectivity of 3,5-diaminotriazoles – Spermine Oxidases:
Yet another amine oxidase with close homology to LSD1 is the polyamine
enzyme, spermine oxidase (SMO). In fact, the initial discovery of LSD1 can be
attributed to work with SMO.161 Despite this close relationship, many studies of
LSD1 inhibitors fail to consider SMO in their off-target screening. However, we
included SMO in our study because of previously reported roles for SMO and
polyamines in kidney and liver ischemia-reperfusion.162 For example, the
oligoamine LSD1 inhibitor, verlindamycin (5), showed significant potency in
reduction of SMO and N-acetyl polyamine oxidase (APAO) activity at 10 µM
(Figure

4.3A).

To

screen

our

compounds,

we

performed

a

simple

chemiluminescent assay using recombinant SMO, as previously described.163 In
short, the stoichiometric production of H2O2 was quantified using luminol and
horseradish peroxidase. In addition, we used MDL72527 (Compound 11), as a
positive control (IC50SMO < 10 µM).164 We showed that both compound 9 and 10
showed significant SMO potency, with an IC50 = 40 nM and 180 nM, respectively
(Figure 4.3B). Interestingly, this is the most potent small molecule inhibitor of
SMO described yet. Therefore, future exploration into derivatives of the 3,5diamino-1,2,4-triazole may be warranted as potent SMO inhibitors.
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A.

B.

Figure 4.3. LSD1 inhibitors exhibit potency against SMO. A
chemiluminescent assay was used to screen LSD1 inhibitors. (A)
Recombinant SMO and APAO was treated with 1 µM verlindamycin. (B)
Titration analysis of compound 9 and 10 indicated IC50 = 40 nM and
180 nM, respectively. Data indicates replicates of three separate
experiments with n=4-6 wells per treatment. Mean ± SEM.
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SMO inhibitor MDL72527 does not inhibit LSD1:
Our 3,5-diamino-1,2,4-triazole compounds showed significant efficacy for
two enzymes – LSD1 and SMO.

Therefore, we aimed to characterize the

selectivity of known inhibitors of these individual enzymes.

The selective,

enzyme-activated irreversible SMO inhibitor, MDL72527, is a potent micromolar
inhibitor of SMO (Figure 4.4A-B). However, no studies have shown whether or
not this compound showed additional efficacy for LSD1. We performed an LSD1
inhibition assay, as previously described165, and titrated MDL72527 up to 100
µM. MDL72527 lacked any inhibition of LSD1, and thus, demonstrated it as a
SMO selective inhibitor (Figure 4.4C).

LSD1 inhibitor GSK-LSD1 does not inhibit SMO:
Similarly, we aimed to establish the potency of a known selective LSD1
inhibitor against SMO. GSK-LSD1 (Figure 4.5A) has a selectivity index of >1000
for MAO-A, MAO-B, and LSD2.166 However, no studies have been performed
with SMO.

We performed a standard SMO inhibition assay, as previously

described.163 GSK-LSD1 did not show any significant inhibition of SMO (Figure
4.5B). Therefore, GSK-LSD1 is a highly selective for LSD1.
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A.	
  	
  

	
  

	
  

MDL 72527

B.

C.

Figure 4.4. SMO inhibitor MDL72527 selectivity. (A) MDL72527
structure. (B) Recombinant SMO assay shows IC50(SMO) = 1.5 µM (C)
Recombinant LSD1/CoREST assay. Data indicates replicates of three
separate experiments with n=4-6 wells per treatment. Mean ± SEM.
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A.

GSK-LSD1

B.

C.

Figure 4.5. LSD1 inhibitor GSK-LSD1 selectivity. (A) GSK-LSD1
structure. (B) Recombinant SMO assay shows IC50(SMO) >100 µM. (C)
Summary of amine oxidase inhibitors’ selectivity. Data indicates
replicates of three separate experiments with n=4-6 wells per treatment.
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Differential inhibitors of LSD1, SMO, and MAO:
In summary, our recombinant enzyme screens of 3,5-diamino-1,2,4triazoles, MDL72527, GSK-LSD1, and verlindamycin demonstrated distinct uses
for each compound to dissect individual enzyme roles within cardiopathology
(Figure 4.5C). Verlindamycin is the least selective, showing efficacy for all four
amine oxidases tested (Table 4.1), making it a pan-amine oxidase inhibitor. Our
newly designed 3,5-diamino-1,2,4-triazoles both showed significant potency for
LSD1 and SMO. Interestingly, compound 9 favored SMO with almost 30-fold
more potency. Therefore, 3,5-diamino-1,2,4-triazoles are dual inhibitors of LSD1
and SMO. Finally, we confirmed the selectivity of both MDL72527 and GSKLSD1 for SMO and LSD1, respectively.
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Table. 4.1. Amine oxidase inhibitor classes and selectivity for LSD1, MAOs, and SMO.

3,5-diaminotriazoles show limited cytotoxicity :
The field of LSD1 drug development primarily focuses on compounds
highly efficacious at cancer cell killing. However, LSD1 has emerged as a drug
target in diseases other than cancer. As such, there is a need for epigenetic
inhibitors that preclude overt cytotoxicity. Therefore, cellular characterization of
these compounds focused on identifying compounds with decreased cytotoxicity
in multiple cell lines.
In order to identify hits that showed a reduction in cytotoxicity, compounds
exhibiting in vitro IC50 < 5 µM were screened by a standard MTS reduction
assay and verified by simple nuclei staining quantification.

Multiple cell lines

were screened, including CALU-6, MCF7, MCF-10a, MDA-MB-231, CA46, PC3,
and PANC1. Table 4.2 shows a brief description of each of these cell lines.
Cultures were grown in appropriate media as per ATCC instructions at 37oC in a
humidified environment containing 5% CO2. The cells were plated and
maintained in a clear bottom, 96 well plate and seeded at 1,000 cells/ well. After
attachment, compounds were titrated from 500 nM-100 µM for 48 hrs. The cells
were exposed to DMSO concentrations of less than 1%, and 1% DMSO was
used as a negative control for cell growth. The known LSD1 inhibitor
verlindamycin 5 was used as a positive control. A tetrazolium salt [3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, inner salt; MTS] is added and cleaved by intracellular esterases to
form a colorimetric solution and quantified by spectrophotometry. In addition,
cells were fixed with 4% PFA, permeabilized with 1% Triton-X100 and stained
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with DAPI at 1:1000 with in PBS. Nuclei were then counted by high throughput
immunofluorescence microscopy.
CALU-6 human lung adenocarcinoma cells express high endogenous
levels of LSD1, and thus, are responsive to LSD1 compound treatments
Compound 9 and 10 were not cytotoxic to cultured CALU-6 cells (IC50 > 100 µM),
while the internal standard verlindamycin (5) was cytotoxic with an IC50 = 5 µM
(Figure 4.6A). The negative control tranylcypromine, a known low toxicity
compound, was cytotoxic at IC50 ~ 1 mM (Figure 4.6B).
The cytotoxicity of 9 and 10 was examined in five additional cell lines
including CA46 Burkitt’s lymphoma, the PC3 human prostate cancer cell line, the
PANC1 human pancreatic cell line, the MDA-MB-231 estrogen receptor-negative
cell line and the MCF-10A human breast epithelial cell line. LSD1 has been
shown to be overexpressed in the PC3, PANC1 and MDA-MB-231 cell lines.
Compounds 9 and 10 produced no significant cytotoxicity in the CA46 and MCF10A lines, although 9 had an IC50 of 52 mM in the MCF-10A line (Figure 4.7A-C).
In the PC3 line, both 9 and 10 exhibited IC50 values near 74 mM, compared to
the internal standard 5, which produced 85% growth inhibition at 8 mM (Figure
4.8A). In the PANC1 and MDA-MB-231 lines, 10 was not an effective growth
inhibitor, with IC50 values of 80 and 55 mM, respectively. Interestingly, compound
10 was an effective growth inhibitor in the PANC1 and MDA-MB-231 cell lines,
exhibiting IC50 values of 19 and 12 mM (Figure 4.8). The mechanism underlying
this activity remains to be determined; however, it can be generally stated that 9
and 10 produce little cytotoxicity in multiple cell lines in vitro.
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Table 4.2. Human immortalized cell lines and descriptions.

A.

B.

Figure 4.6. Cell viability and compound cytotoxicity in Calu-6. Cells
were seeded at 3x103 cells/well and treated 48-72 hrs with increasing
concentrations of 2, 5, 9, and 10. Cell viability was determined by
colormetric CellTiter 96 Aqueous MTS (Promega, #G3580). Data indicates
replicates of three separate experiments with n=4 wells per treatment.
Mean ± SEM.
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A.

B.

C.

	
  
Figure 4.7. Cell viability in MCF-10a (A), MDA-MB-231 (B), and CA46
(C). Cells were treated 48-72hrs with increasing concentrations of 5, 9, and
10. Cell viability was determined by colormetric CellTiter MTS (Promega,
#G3580). n=4 wells per experiment run in triplicate. Mean ± SEM.
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A.

B.	
  

Figure 4.8. Cell viability and compound cytotoxicity in PC3 (A) and
PANC1 (B). Cells were treated 48-72 hrs with increasing concentrations of
2, 9, and 10. Compound 5 was used at a fixed 8 µM concentration as an
internal control. Cell viability was determined by colormetric CellTiter 96
Aqueous MTS (Promega, #G3580). Data indicates replicates of three
separate experiments with n=4 wells per treatment. Mean ± SEM.
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Cellular phenotype and histone methylation changes of 3,5-diaminotriazoles:
To measure the cellular effects of 9 and 10, treated cells from the
cytotoxicity assay above were stained for immunofluorescence imaging using the
appropriate fluorescently labelled secondary antibodies. In a 96-well plate, 5%
BSA was added to specific wells and the plate was allowed to stand for 2 hours.
The plate was then incubated at 4oC overnight with the primary antibody for
H3K4me2. Fluorescent secondary antibodies were then added to each well at
1:500 dilutions in 1% BSA for 2 hours. Cells were washed, suspended in PBS
and viewed for intensity of signal per cell (Hermes WiScan, Idea Biomedical).
The imaging system is able to generate 10-40x images as well as quantify
average intensity on a per-well basis, eliminating any bias towards fluorescent
staining. Compounds 9 and 10 at both 1 and 10 µM developed green
fluorescence in the nucleus at 48 hours that was comparable to the fluorescence
promoted by 30 µM tranylcypromine, indicating a significant increase in
H3K4me2 levels (Figure 4.9A). The H3K4me2 levels were quantified and
graphed as cell count vs. average intensity (RFU) as shown in the histogram
(Figure 4.9B). The mean population intensity (MPI) ± SEM for the vehicle was
1.44x104 ± 71 RFU. In comparison, the MPI for 30mM TCP was 1.86x104 ± 136
RFU (1.3-fold increase), for 10 mM compound 9 1.82x104 ± 105 RFU (1.26-fold
increase), and for 10mM compound 10 1.91x104 ± 124 RFU (1.33-fold increase).
Thus, 9 and 10 1µM were as effective as 30mM TCP at increasing H3K4me2 in
vitro. Western blot analysis of cell lysates were also performed to show a dose
response increase in global methylation (Figure 4.9C).
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Figure 4.9. Global methylation changes. (A) CALU-6 cells were treated
with 30µM TCP (2), 1µM 9, or 1µM 10 for 48hrs. Cells were stained for
nucleus (DAPI), F-actin (Alexa Fluor 594 Phalloidin), and dimethyl-H3K4
(Alexa Fluor 488 Secondary Antibody). (B) Fluorescent intensity on cellby-cell basis was obtained by Hermes WiScan (IDEA Biomedical) and
graphed as a frequency distribution histogram of relative cell count at
specific intensities. (C) Western blots of histone methylation. Two-way
ANOVA; * P-value < 0.001, representative of 3 experiments with n=4 wells.
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Disruption of Epigenetic Complexes in Primary Cardiomyocytes:
LSD1 activity at chromatin promoters is facilitated through binding in large
epigenetic complexes. LSD1 is found in the CoREST/REST/HDAC corepressor
complex and extensive crosstalk takes place amongst each enzyme. Therefore,
we hypothesized that since HDAC inhibition within these complexes have shown
cardioprotection, LSD1 inhibition could show similar results. In fact, we wanted
to explore if LSD1 inhibition was sufficient to disrupt the CoREST:LSD1
interaction. Primary rat cardiomyocytes were isolated by hanging heart method
as previously described.167 Cardiomyocytes were treated at concentrations
equivalent to their IC50-values for 3-hours. Cell lysates were pulled-down with
LSD1 and immunoblotted for CoREST. Figure 4.10 shows that compound 9
considerably disrupted the LSD1:CoREST interaction. Interestingly, neither
verlindamycin nor compound 10 were able to replicate this phenomenon so
acutely. HDAC1 and total protein lysate were used as loading controls.
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Figure 4.10. Primary rat cardiomyocytes provide preliminary data on 3,5diamino-1,2,4-triazoles efficacy in vitro to disrupt co-repressor
complexes. Co-immunoprecipitation analysis for LSD1:CoREST complex
following treatment with 5 µM VLM, 1 µM 9, 2 µM 10. Lysates pulled down
with LSD1 antibody and immunoblotted for CoREST. Data representative of
three separate experiments.
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Toxicology screen of Compound 9 in CD1 mice:
A pilot toxicology study in four CD1 mice was performed in collaboration
with the MUSC Veterinary Services. In short, a 3 mg/kg, intraperitoneal injection
of compound 9 was administered daily for 1-week. After the drug course, mice
were evaluated by the MUSC veterinarian.

A complete blood panel, liver

enzymes, and kidney functional labs were obtained, followed by histological
evaluation of various organs (i.e. heart, lung, liver, spleen, and kidney).

A

comprehensive report on histological damage was obtained by a veterinary
pathologist. In addition, a consultation with an MUSC Hematology Resident and
Nephrologist were also performed.
Upon gross examination, all four mice showed no abnormalities or
contraindications from drug treatments. The blood panel and liver enzymes had
no outstanding findings and were within normal range. However, blood urea
nitrogen (BUN) was elevated, creatinine was low, and blood glucose was
elevated (Table 4.3). Thus, the BUN:Creatinine ratio was higher than reported
normal values. In addition, the CBC showed minor thrombocytopenia.
Histological evaluation by hemotoxylin and eosin staining of various
organs revealed very minimal to minor pathological changes. Of note, the kidney
showed minor ectatic cortical tubules with attenuated epithelium (Figure 4.11A).
In addition, the heart showed minor vacuolation of cardiomyocytes without any
interstitial immune infiltration (Figure 4.11B). There was also negligible multifocal
hepatic inflammation and necrosis (Figure 4.11C). Finally, the spleen showed no
outstanding lesions (not shown).
	
  

111	
  

Table 4.3. Clinical laboratory values (mean ± SEM)
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Figure 4.11A. Kidney histology of Compound 9 treated CD1 male mice
(3mg/kg, i.p., QD 7 days). Hemotoxylin and eosin staining of cortical kidney.
Mild multifocal ectatic tubules with attenuated epithelium (Arrow). Limited
tubular hyperplasia and regeneration. (Reported in 2 of 4 animals).

	
  

113	
  

Figure 4.11B. Heart histology of Compound 9 treated male CD1 mice
(3mg/kg, i.p., QD 7 days). Hemotoxylin and eosin staining of left ventricular
free wall. Mild diffuse cardiomyocyte intrasarcoplasmic vacuolation without
interstitial infiltrate. (Reported in 2 of 4 animals)
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Figure 4.11C. Liver histology of Compound 9 treated male CD1 mice
(3mg/kg, i.p., QD 7 days). Hemotoxylin and eosin staining of left lobe. Mild
multifocal hepatic inflammation and necrosis can be found, as indicated by the
arrows. (Reported in 3 of 4 animals)
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III. DISCUSSION
Current inhibitors of amine oxidases show significant undesirable potency
towards other members of the family. This is due to, in part, because of the high
sequence homology within the active sites. As such, we began to test newly
designed LSD1 inhibitors for efficacy against other amine oxidases, including
MAO-A, MAO-B, and SMO. In addition, the vast majority of LSD1 inhibitors were
designed as antitumor agents, with the explicit goal of cancer cell toxicity.
Recently, however, increasing evidence demonstrates a focus for epigenetic
manipulation outside the realm of cancinogenesis.155-159 In particular, we were
interested in the role of LSD1 in CVD, and thus, intended to manipulate
epigenetic enzymes without causing drug-driven cellular damage. Therefore, we
evaluated our compounds for cytotoxicity in multiple cell lines and during a small
toxicology study. Finally, we performed a coimmunoprecipitation assay of the
CoREST:LSD1:HDAC corepressor complex to determine whether LSD1
inhibition in cardiomyocytes disrupted this epigenetic complex.
Our initial evaluations of the selectivity of compounds 9 and 10 place them
among the first reversible small molecule compounds that possess selectivity for
LSD1 over MAO A and B. However, they also observe considerable inhibition
against SMO. Therefore, the 3,5-diamino-1,2,4-triazole scaffold is, in fact, a dual
inhibitor per say. In other words, these compounds can be utilized as agents to
target both LSD1 and SMO. Interestingly, both enzymes may be playing a
detrimental role in IR remodeling162 and inhibition of both amine oxidases could
prove beneficial as a treatment strategy.
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The dual selectivity of compound 9 and 10 for LSD1 and SMO, although
potentially useful as a therapy, severely limits their utilization as a tool to unveil
LSD1 as a key new therapeutic target. Therefore, we evaluated current LSD1
and SMO inhibitors for cross-reactivity.

In particular, we aimed to find

compounds that could inhibit one enzyme, but not the other. A few months prior
to this dissertation, a highly selective irreversible LSD1 inhibitor was made
commercially available.166 This compound, 3, did not show any inhibition of SMO.
Likewise, we were able to find an irreversible SMO inhibitor, MDL72527, that did
not affect LSD1 activity.164 These compounds will be utilized in future
cardiovascular experiments to dissect the individual contributions of each
enzyme in 3,5-diamino-1,2,4-triazole mediated cardioprotection (see Chapter 5).
Compounds 9 and 10 also produce the desired epigenetic effect, namely a
significant increase in H3K4me2 levels, indicating that they enter mammalian
cells and are active within the cell nucleus.

This was confirmed by our

coimmunoprecipitation results in primary rat cardiomyocytes. In particular, these
results implied that compounds 9 and 10 could reduce LSD1 activity and
indirectly influence the activity of HDACs. In addition, the low level of toxicity to
mammalian cells produced by 9 and 10 demonstrate that the 1,2,4-triazole
scaffold can be used to produce LSD1 inhibitors that can be used in non-cancer
disease states.
Preliminary results in a pilot study (discussed further in Chapter 5)
indicated that an LSD1 inhibitor could protect the heart against IR injury.
Therefore, to continue our preclinical evaluation of the 3,5-diamino-1,2,4-triazoles
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scaffolds as potential cardiac candidates, we began to evaluate the in vivo
toxicity using CD1 mice. With the assistance of the MUSC Veterinary Services,
an MUSC hematology resident, and a nephrologist, we were able to evaluate any
damage caused by intraperitoneal injections of 3 mg/kg compound 9. We
demonstrated that the compound showed minimal to mild histological damage to
the kidney, liver, and heart. Of most interest, there was mild vacuolation of the
sarcomeres within cardiomyocytes.

This can be a precursor to cardiotoxic

changes such as degeneration, or an age-related incidental finding. In short-term
toxicology studies, treatment-related myocardial degeneration was characterized
by multifocal myocardial and interstitial vacuolation, often associated with diffuse
interstitial cellular infiltration consisting of macrophages and neutrophils.168 These
small to large vacuoles seen within sarcoplasm presumably represent
degenerate myofibrils. Yet, in some drug studies, cellular infiltration was the sole
insult seen. As such, minor multifocal sarcoplasmic vacuolation without
accompanying cellular infiltration can be a relatively frequent event in control
mice. Therefore, within the scope of this small, pilot toxicology study, we cannot
rule-in or rule-out this finding as compound-induced toxicity.
In addition to the histology, we saw that the BUN:Creatinine ratio and
blood glucose were elevated. A simple explanation for this could be that the mice
were dehydrated, although no definitive laboratory test is available for this.
Dehydration would cause decreased blood volume to be filtered to the kidneys,
and as such, cause elevated BUN:Creatinine ratio. In addition, dehydration can
lead to elevated blood glucose (i.e. vasopressin is produced by the kidneys to
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compensate for dehydration, leading to gluconeogenesis in the liver). In order to
rule out prerenal azotemia (i.e. elevated nitrogen-containing compounds),
additional laboratory tests need to be performed, such as albumin.
In summary, we successfully identified compound 9 and 10 as dual
inhibitors of LSD1 and SMO, with limited efficacy against MAOs. In addition, we
confirmed these compounds successfully traversed the cell membrane and
produced prolific epigenetic changes. Compounds 9 and 10 are also the first
designed reversible inhibitors of LSD1 and potent SMO dual inhibitors to date.
Augmented by their low toxicity, these compounds show promise as cardiac drug
candidates.

IV. LIMITATIONS AND FUTURE DIRECTIONS
Compounds 9 and 10 did not show efficacy against MAO-A or B.
Therefore, we do not expect to see many of our 3,5-diaminotriazole derivatives
inhibit MAO-A or B as well.

However, newer –azole family of fungicides

incorporate the 1,2,4-triazole moiety and are potent CYP450 enzyme
inhibitors.169-170 For instance, posaconazole is an extended spectrum antifungal
with clinical concerns because of its CYP3A4 potency.171 Therefore, our new
compounds may show concern with drug-drug interactions.

Finally, triazole

drugs have been shown to be extensively first-pass metabolized by CYP2C19.172
One primary concern is the population polymorphisms that exist with CYP2C19
and needs to be considered as preclinical work continues with these compounds.
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Despite successful previous work in CALU-6 cells that express high
endogenous LSD1, LSD1 still makes up just one of a vast multitude of histone
demethylases in the cell, some of which have similar substrates.173 Thus, LSD1
inhibition or removal may not be detectable on a global histone level.

For

instance, LSD1 knockout HCT116 cells failed to show any changes in global
histone methylation.174 LSD1 occupies approximately 2% of genomic promoters
in corepressor complexes in stem cells.175 Thus, LSD1 inhibition can alter gene
transcription on a local level, without showing global changes.

Therefore, a

chromatin immunoprecipitation (ChIP) at known LSD1-regulated promoters may
need to be done to verify target inhibition. Also, a recently published manuscript
on using CD86 cell surface receptor as an LSD1 biomarker could also be
evaluated.176
The dual inhibition of SMO and LSD1 make future drug development
intriguing. For instance, compound 9 and 10 demonstrate for the first time, a
reversible, competitive small molecule inhibitor of LSD1. Yet, they also present
the most potent SMO inhibitors to date. Therefore, extensive lead optimization of
these compounds in both settings, SMO and LSD1, need to be explored. Early
hit-to-lead studies suggest that we are able to identify more potent analogues. In
addition, not all LSD1 inhibitors are effective against SMO, and vice versa.
Therefore, it is not unreasonable to think that future evaluation of related
analogues can diverge this dual inhibition. However, in the setting of cardiac
ischemia-reperfusion injury, a dual inhibitor, such as 9, may be beneficial
because of the roles SMO and LSD1 both play in cardiopathology.
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Furthermore, additional studies need to measure the interactions of these
compounds with cytochrome P450 enzymes to eliminate undesirable side-effects
early in drug development. As stated earlier, 1,2,4-triazole structures are firstpass metabolized by CYPs within the liver. In addition, Sorna et al. published
LSD1 inhibitors with moderate CYP450 interactions of their benzohydrazide
series. Therefore, these compounds will be screened for activity against relevant
CYP450 enzymes utilizing the Vivid SelectScreen CYP450 Screening kits
(Invitrogen).
Finally, our pilot toxicology study was severely limited by our low sample
size and lack of controls. We performed this study as a snapshot of toxicity and
compared our values to well-established laboratory values and histology of
health CD1 mice. However, many of the lesions we saw within tissues were
inconclusive because of these limitations. When further testing is performed, it
will be important to look at increased numbers of animals, multiple doses of
compounds, and both sexes.
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CHAPTER 5: LSD1 as a novel therapeutic target to mitigate post-IR
contractile dysfunction and infarction
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I. INTRODUCTION
Current clinical therapies to achieve whole organ recovery following cardiac
ischemia remain insufficient and are limited to reestablishing flow by primary
percutaneous coronary intervention shortly after ischemic insult. However,
reperfusion itself is detrimental at the cellular level and can lead to arrhythmias,
mechanical dysfunction, and cell death.177 We strove to unveil a previously
unidentified enzyme target to improve recovery after an AMI by limiting
reperfusion injury. In short, we aim to modulate pro-survival signaling and
preconditioning

responses

through

pharmacological

manipulation

of

the

epigenetic enzyme, LSD1.
Ischemia-reperfusion (IR) is a multifaceted pathological condition involving
changes

in

inflammatory

signaling,

Ca2+

balance,

and

transcriptional

reprogramming.178 Formation of oxyradicals during IR leads to lipid peroxidation
and sulfyhydryl oxidation, resulting in membrane leak and intracellular protein
denaturing.177 An effective method to reduce the damage caused by IR is by the
phenomenon

of

ischemic

preconditioning.179

However,

the

underlying

mechanism as to how a tissue becomes “ischemia tolerant” remains obscure.
One explanation is the activation of the reperfusion injury survival kinase (RISK)
signaling cascade, and thus, favoring pro-survival kinases during anoxia.180
Another is the upregulation of oxidant scavenging enzymes superoxide
dismutase (SOD2) and catalase by preconditioning.181 This reduces the overall
milieu of reactive oxygen species capable of causing oxidative stress.

	
  

123	
  

In recent years, increasing evidence indicates that chromatin-remodeling
processes such as histone demethylation and deacetylation play crucial roles in
gene regulation during pathological cardiac events (e.g. IR injury) and cardiac
preconditioning. To date, HDAC inhibitors, such as suberoylanilide hydroxamic
acid (SAHA), have been beneficial in maintaining cardiac contractility and
reducing infarct area post-IR injury.182 For instance, when administered before
and at the time of reperfusion, SAHA partially rescued systolic function.183
Increasing evidence indicates that class I HDACs crosstalk and act in tandem
with LSD1 within the CoREST/LSD1/HDAC corepressor complex at similar
promoters.184 As such, previous studies have shown how class I HDAC inhibitors
can increase histone methylation as well.184 Therefore, we hypothesized that
LSD1 inhibitors could also be applied as cardioprotective agents. This study is
the first known attempt at utilizing this innovative strategy in CVD.
The ensuing chapter focuses on the identification of LSD1 as a novel
therapeutic target in CVD by utilizing amine oxidase-specific inhibitors. Also, we
will illustrate preclinical testing of our novel 3,5-diamino-1,2,4-triazole, 9, as a
potential cardiac drug candidate. As discussed in Chapter 4, compound 9
exhibits many characteristics of a successful cardiac clinical compound, such as
its fairly nontoxic nature in vitro and in vivo. However, our understanding of the
mechanism of action and importance of LSD1 is limited by the dual inhibition of
9.

In particular it shows efficacy against two enzymes, LSD1 and SMO.

Therefore, in order to isolate LSD1 as a causative target during IR damage, we
employed other selective compounds as tools to determine the mechanism of
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action of 9. We will use a well-documented SMO-specific inhibitor (i.e.
MDL72527) and a highly potent LSD1-specific compound (i.e. GSK-LSD1).
We will test our hypothesis using two murine models of IR injury. First, we
will test the effectiveness of test compounds in an ex vivo isolated heart model.
This model is an effective tool in early drug discovery because it is highly
reproducible and can accurately control drug concentrations. Most importantly, it
provides a specific method of action by a compound at the tissue level that
precludes any systemic, immune, and circulating stress factors. However,
excising a whole organ from an animal moves our results farther from clinical
resemblance, and thus, an additional model was considered. Therefore, in order
to confirm our ex vivo results, we performed an in vivo coronary ligation and
reperfusion model as well. It provides a more clinically relevant IR injury and
allows observation of myocardial recovery at longer time points.
Figure 5.1 demonstrates the workflow progression utilized in this chapter.
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Figure 5.1. Chapter 4 workflow chart and preclinical testing of compound
9. A pilot study was performed with a known LSD1 inhibitor, verlindamycin (5).
From this, preclinical testing of lead compound 9 was performed using two
murine models of IR injury. Additional studies were performed with MDL72527
(compound 11), an SMO-specific inhibitor, and GSK-LSD1 (compound 3), an
LSD1-specific inhibitor. IR = ischemia-reperfusion, LAD = left anterior
descending coronary artery, QD = per day, i.p. = intraperitoneal, CO = cardiac
output, LVEDV = left ventricular end diastolic volume, EF% = ejection fraction,
FS = fractional shortening, SMO = spermine oxidase
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Goals of Chapter 5:
1.) Assess the levels of LSD1 during IR injury and its
correlation to severity of cardiac dysfunction.
2.) Pilot study: Determine if the pan-amine oxidase inhibitor,
verlindamycin, protect the heart from IR damage.
a. Does verlindamycin reduce infarction?
b. If so, is this preconditioning through the RISK prosurvival signaling pathway?
c. Does LSD1 inhibition increase antioxidants, such
as catalase?
3.) Determine the efficacy of novel 3,5-diamino-1,2,4-triazole
(9) to sustain cardiac function and structure, similar to the
results found in our pilot study.
4.) Use SMO and LSD1-specific irreversible inhibitors to
reveal the mechanism of action of compound 9 and
identify LSD1 as a novel therapeutic target in CVD.
5.) Observe chronic cardiac remodeling in a more clinically
relevant model of IR injury.
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II. RESULTS
LSD1 protein is increased within infarcted tissue following IR injury and levels of
protein expression correlate to severity of cardiac contractile dysfunction:
The induction of LSD1 activity by hypoxia has previously been shown in
carcinogenesis185 and DNA mismatch repair silencing by CoREST/HDAC/LSD1
corepressor complexes.186 Interestingly, Zhang et al. were the first to show that
LSD1 expression itself was responsive to transient global cerebral ischemia.

187

They demonstrated that LSD1 spatially and temporally increased in response to
IR in the brain.187 Therefore, we aimed to evaluate the expression status of LSD1
in response to IR injury.
The left anterior descending coronary artery (LAD) in CD1 mice was
surgically ligated for 40-mins as described earlier. (Chapter 2, “Left anterior
descending coronary ligation-reperfusion in vivo IR”). After 7-days post IR
surgery, the infarcted tissue distal to the LAD ligation was homogenized and
immunoblotted for LSD1. Similar to the induction of LSD1 previously reported by
cerebral IR187, we saw a significant increase in LSD1 protein (Figure 5.2A).
We also were interested in the correlation between LSD1 protein
expression and cardiac function. In order to determine any correlation between
the two, we analyzed infarcted tissue from mice after 5-days, 7-days, and 14days post LAD ligation. Echocardiograph data of ejection fraction and LV end
diastolic volume were observed and compared to individual LSD1 protein levels.
A scatterplot of cardiac function vs. LSD1 protein was graphed (Figure 5.2B-C).
In hearts demonstrating more detrimental cardiac function (i.e. reduced ejection
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fraction and increased LV dilation), more abundant LSD1 protein was present. A
nonparametric Spearman correlation analysis was performed (GraphPad
Prism6). In comparison to LSD1 protein expression, ejection fraction and LV end
diastolic volume demonstrated Spearman correlation coefficients of -0.7636
(95% confidence interval -0.9377 to -0.2835, p-value 0.0098) and 0.7909 (95%
confidence interval 0.3456 to 0.9455, p-value 0.0055), respectively. A linear
regression of the correlation study successfully showed a significant deviation of
the slope from zero (p-value=0.0024 and 0.0067, respectively). Therefore, these
results indicate that an increased expression of LSD1 is correlated with larger LV
dilation and lower EF.
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A.

B.

C.

Figure 5.2. LSD1 increases within the infarction following IR. (A)
LSD1 in 7-day lysates following LAD ligation-reperfusion. (B)
Correlation of ejection fraction vs. LSD1 protein (C) LV end diastolic
volume vs. LSD1 protein. Each data point represents one mouse.
Spearman r = -0.7636 (EF vs. LSD1); r = 0.7909 (LVEDV vs. LSD1)
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Pilot study – Verlindamycin sustains cardiac function and reduces infarct area
following IR injury:
In order to determine whether LSD1 inhibition could blunt myocardial IR
injury, we conducted a pilot study using a known LSD1 inhibitor. Our lab
published the design of a noncompetitive, (bis)biguanide oligoamine derivative
(Verlindamycin, VLM; Chapter 1, Figure 1.12, Compound 5) as a potent
inhibitor of LSD1, which causes significant increases in global histone
methylation.188 To test our hypothesis, we used an ex vivo isolated heart model
of cardiac ischemia-reperfusion injury (Chapter 2; Langendorff ex vivo
retrograde perfusion isolated hanging heart model).

This model was

beneficial because it is highly reproducible and within self-sustaining cardiac
tissue. Male Sprague-Dawley rats were treated with VLM (10mg/kg, i.p.) at 18and again at 1-hr prior to excision of the heart onto the retrograde perfusion
apparatus as previously described. A saline-filled balloon attached to a pressure
transducer was inserted into the left ventricle (LV) and cardiac pressure traces
were obtained.

Following 10-minutes of baseline function, transient global

ischemia was performed for 30-minutes, followed by reestablishment of
retrograde flow for 1-hour (Figure 5.3A.

Hearts treated with verlindamycin

maintained left ventricular developed pressure (LVDP) due to its improvement of
end diastolic pressure (LVEDP, Figure 5.3B). LV end systolic pressure did not
change between treatment groups. This experimental observation was
reproduced with tranylcypromine (2), a less potent LSD1 inhibitor. Therefore,
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two LSD1 inhibitors with different mechanisms of action produced an acute
functional protection in the isolated heart model.
In addition, we also demonstrated that both LSD1 inhibitors decreased
infarct area when the hearts were transverse sectioned into 2-mm slices and
incubated in 1% 2,3,5-triphenyltetrazolium chloride (TTC) for damaged tissue
(Figure 5.4). In brief, TTC is enzymatically reduced in metabolically active cell
dehydrogenases, forming a visible red dye. Therefore, tissue that shows white
areas are considered necrotic or infarcted tissue. VLM and tranylcypromine both
showed significantly less infarcted tissue than vehicle-controlled hearts.
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A.

B.

	
  

Figure 5.3. Verlindamycin; contractile recovery upon reperfusion in
isolated male rat hearts after 30mins ischemia. (A) Timeline VLM
treatments prior to heart isolation. (B) A saline-filled balloon fixed to a
pressure transducer attached in the LV measured contractile function.
Experimental groups (n=6) were injected 18hrs and 1hr prior to ischemia
with 10 mg/kg, i.p. VLM or DMSO Vehicle. *p<0.001. Mean ± SEM.
	
  

133	
  

A.

B.

	
  
Figure 5.4. Infarct area in isolated rat hearts treated with LSD1
inhibitors. (A) Triphenyltetrazolium chloride (TTC) is a soluble redox
indicator dye that is enzymatically converted by metabolically active, or
live, cells to a red dye. Lack of staining (i.e. white) indicates infarction.
(B) Following IR, rat hearts were sliced in 2-mm sections and incubated
with 1% TTC at 37°C for 15mins and then fixed in formalin prior to
photomicrography.
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Pilot study – Verlindamycin treatment preconditioning of the heart was not
achieved via the canonical RISK signaling pathway:
Verlindamycin (VLM) sustained cardiac function and reduced infarction in
pretreated rats. This led us to hypothesize that LSD1 may be upregulating by
traditional survival preconditioning signaling in cardiomyocytes. This includes
activation of PI3K and its downstream targets Akt, p70S6K, and ERK1/2. These
kinases are deemed the Reperfusion Injury Survival Kinase (RISK) pathway.179
Following the 1-hour of reperfusion, the Langendorff hearts were
homogenized for protein analysis and immunoblotted for activation of key
kinases in the RISK pathway. All of the kinases downstream of PI3K signaling
are activated through dual phosphorylation of serine and/or threonine residues.
Therefore, we aimed to see if preconditioning by VLM caused increases in
phosphorylation. Interestingly, p-Akt and p-MAPK/ERK were not changed in
VLM-treated hearts when normalized to the loading control GAPDH (Figure 5.5).
Another focus in ischemic preconditioning has been on p38 MAPK
signaling. However, its role still remains controversial because of the differential
biological functions of various isoforms. The two primary isoforms found in the
heart are p38α and p38β (Figure 5.6A). P38α is thought to mediate apoptosis,
whereas p38β activation can lead to cardioprotection and anti-hypertrophic.189
We found that VLM increased phosphorylation at threonine-180 and tyrosine-182
of p38β by 6-fold as compared to non-treated IR hearts (Figure 5.6B).
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A.

B.

Figure 5.5. RISK survival signaling during IR injury. (A) RISK
signaling. (B) Western blot of phosphorylation of Akt and ERK, both
activating modifications in RISK signaling. Densitometry showed no
significant differences between wells.
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A.

B.

	
  

Figure 5.6. Isoform-specific roles of p38 during IR injury. (A) p38
signaling (B) Western blot of phosphorylation of p38β. Densitometry
showed a 6-fold increase in p-P38 in drug treated. N=4, * p-value < 0.05
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Pilot

study

–

Pretreatment

with

verlindamycin

increased

endogenous

antioxidants:
Since a high influx of reactive oxygen species, including H2O2, takes place
during IR injury, increasing the general antioxidant milieu, in theory, should limit
the amount of oxidative damage caused during IR injury. One such antioxidant
enzyme, catalase, reduces hydrogen peroxide (H2O2) to water and molecular
oxygen. In order to determine any changes in catalase levels, rat hearts from our
pilot study were homogenized and resolved by Western blotting (Figure 5.7A).
VLM increases endogenous catalase protein during IR injury by nearly 80%.

Pilot study – Evaluate histone methylation changes by verlindamycin:
In vitro studies in cancer have shown a dose-dependent global increase in
histone methylation (i.e. H3K4me2) with VLM.188 However, these studies were
performed in cells that are highly responsive to LSD1 inhibition. We aimed to
evaluate whether global changes in histone methylation could be observed in our
pilot study.

In particular, because VLM treatment caused an increase in

endogenous catalase, we hypothesized that this phenomenon was due to
inhibition of LSD1/CoREST/HDAC1 corepressors, resulting in increased catalase
expression.

Contrary to this, western blot analysis of histone modifications

indicated that globally, no change in H3K4me2 was resolved (Figure 5.7B).
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A.

B.

Figure 5.7. Antioxidant quantity and global histone methylation.
(A) Western blot of endogenous catalase protein quantity and
associated densitometry with ImageJ. (B) Western blot of global histone
3, dimethyl lyisne 4 residue. N=4, ** p-value < 0.01. Mean ± SEM.
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Pilot study – in vivo analysis of long-term cardiac function with VLM treatment:
Since a significant improvement of cardiac function and infarction took
place with pretreated mice, our next study looked at more chronic outcomes of
VLM treatment.

Because of the limitations in the isolated heart model, we

designed an experiment using an in vivo IR model, as described earlier (Chapter
2, “Left anterior descending coronary ligation-reperfusion in vivo IR”). CD1
mice were treated with 10mg/kg, i.p. VLM at onset of ischemia and then daily
(Figure 5.8A). The injections were planned for 1-week to allow for significant
cardiac remodeling, fibrosis, and eccentric hypertrophy to take place. However,
after 5-days, the mice experienced abdominal distension from a hypogastric
exudate. Thus, due to the apparent toxic adverse events of the compound, the
study was terminated two days early. An echocardiogram was still performed to
assess cardiac function. Our data failed to show any significance in VLM-treated
versus vehicle controls, but were trending towards a recovery of cardiac function
(Figure 5.8B). Only a sample size of 2-3 mice per experimental group was
performed in this pilot study.
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A.

B.

Figure 5.8. Verlindamycin (VLM) in chronic in vivo IR injury. (A) Timeline
of drug treatments. VLM (3 mg/kg, i.p.) was injected independently at onset
of ischemia and daily for 5 days. The experiment was cut short to 5-days
instead of the planned 7-days due to toxicity of the compound. (B) Male CD1
mice were anesthesized by 3% isoflurane vaporized in 100% O2. The left
anterior descending coronary artery was ligated with 6-0 silk suture and PE10 tubing for 40-min prior to reperfusion. Functional analysis of the heart was
performed by echocardiograph. Heart function analysis was performed by
long-axis and short-axis views using a modified Simpsons method. All pvalues were <0.05 and thus not significant. Mean ± SEM.
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Pilot Study – VLM facilitates cardioprotection by early-onset acute mechanisms:
Our initial experiments with VLM were performed with two intraperitoneal
injections (10mg/kg), at 18-hours and 1-hour prior to heart isolation (Figure
5.3A). Thus, VLM treatments covered both early and late preconditioning
mechanisms. As such, VLM-mediated cardioprotection could be via canonical
LSD1 transcriptional regulation or acute post-translational modification (PTM) of
signaling cascades. In order to investigate which mechanism (i.e. acute PTM or
transcriptional) was being modulated, we performed additional experiments with
VLM administered at only 1-hour prior to Langendorff preparation. Interestingly,
these results were very comparable to our pilot study that involved two injections,
indicating acute LSD1 inhibition could sustain cardiac function (Figure 5.9).
Therefore, this result suggests LSD1 modulation of immediate-early genes by
PTMs

in

signal

transduction

cascades

cardioprotection in our ex vivo model.

	
  

142	
  

may

be

facilitating

the

acute

A.

B.

Figure 5.9. Verlindamycin (VLM) treatments at 1-hr are comparable
to 18hr/1hr treatments. Contractile recovery upon reperfusion in
isolated male rat hearts after 30mins ischemia. (A) End diastolic
pressure and (B) LV developed pressure were measured. Experimental
groups (n=3-6) were injected either 1.) 1hr prior to ischemia with 10
mg/kg, i.p. with compound VLM or 2.) twice at time points 18-hrs and 1hr prior to heart excision. *p<0.001. Mean ± SEM.
	
  

143	
  

The utility of VLM as a cardiac drug and to study LSD1 was limited
by its cytotoxicity and off-target effects. To sufficiently evaluate
the role of LSD1 in IR, we dedicated the remainder of our
physiologic studies to a more attractive cardiac drug candidate,
N3-(2-chloro-6-phenoxybenzyl)-4H-1,2,4-triazole-3,5-diamine.	
  

Novel 3,5-diamino-1,2,4-triazole compound 9 improves acute cardiac function:
Our preliminary ex vivo data with VLM showed substantial promise for an
LSD1 inhibitor as a cardioprotective agent. However, because of the extensive
off-target effects of VLM (Chapter 4, Table 4.1), the exact mechanism of
protection by VLM could not be ascertained. In addition, VLM caused extensive
toxicity after 5-days of treatment. Because of these limitations, we aimed to
utilize a more selective, more potent and less cytotoxic compound as a tool to
understand the role of LSD1 in IR injury.
We began our evaluation using the reversible inhibitor, 9, in the ex vivo IR
model (Figure 5.10A). In particular, 9 shows improved selectivity for LSD1 at
lower doses and precludes the off-target effects on monoamine oxidases
(Chapter 4, Table 4.1). Because we did not know the toxicity of 9 at the time (i.e.
prior to the toxicology results shown in Chapter 4), we chose an acute IR model
where 9 was administered 1-hour before heart isolation (Figure 5.10A). A doseresponse curve was generated to determine the dosage of 9 (not shown). We
found that 3mg/kg treatment was sufficient to maintain LVEDP (87.14 ±
4.6mmHg vs. 57.16 ± 2.8mmHg in vehicle treated) and LVDP (26.70 ± 3.9mmHg
	
  

144	
  

vs. 48.6 ± 5.3mmHg in vehicle treated) after 60-minutes reperfusion following
transient global IR (Figure 5.10B). Interestingly, when the pressure traces of 9
treated rats were examined closer during the anoxia phase, there was a
significant delay in the onset of ischemic rigor contracture (Figure 5.11). The
EDP after 30-min of ischemia was 39.17 ± 2.5mmHg in 9 treated rats, a
significant reduction from 52.31 ± 2.5mmHg in vehicle treated. As projected by a
nonlinear regression (GraphPad Prism6, sigmoid curve, variable slope), the
delay in onset of peak rigor-contractor is approximately 10-minutes. This result
indicates the acute energetics and/or Ca2+-balance in the cardiomyocytes were
improved and thus, suggests that LSD1 inhibition may be influencing their
response to anoxia.
Finally, Infarct area was also assessed, as previously performed with our
VLM pilot study. We stained 2-mm transverse sectioned hearts with 1% TCC.
Compound 9 significantly reduced the infarct area and was equivalent to the
results seen with VLM (Figure 5.12).

	
  

145	
  

A.

B.

	
  

Figure 5.10. Compound 9; contractile recovery upon reperfusion in
isolated male rat hearts after 30mins ischemia. Contractile function
measurements in the LV. Experimental group (n=4) were injected 1hr
prior to ischemia with 3 mg/kg, i.p. with compound 9. *p<0.001. Mean ±
SEM.
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Figure 5.11. Compound 9; Hypoxia-induced rigor contracture.
Pressure trace of end diastolic pressure in compound 9 treated rats.
The dotted red shows a projected peak rigor-contracture delayed by
compound 9. Experimental group (n=4) were injected 1hr prior to
ischemia with 3 mg/kg, i.p. with N3-(2-chloro-6-phenoxybenzyl)-4H1,2,4-triazole-3,5-diamine. Vehicles (n=6) were injected with DMSO.
*p<0.001. Mean ± SEM.
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Figure 5.12. Infarct area in isolated rat hearts treated with LSD1
inhibitors. Following IR, rat hearts were sliced in 2-mm sections and
incubated with 1% Triphenyltetrazolium chloride (TTC) at 37°C for
15mins and then fixed in formalin prior to photomicrography. The white
area indicates zones of infarction. * p-value < 0.05, n=3. Mean ± SEM.
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Dual inhibition of LSD1 and SMOx show cardioprotection from IR injury:
In vitro screening demonstrated that 9 inhibited both LSD1 and SMO
activity (see Chapter 4, Table 4.1). Thus, it is difficult to dissect the individual
roles of each enzyme in the protection afforded by 9. We performed additional
ex vivo Langendorff isolated heart experiments with compounds selective for
each individual enzyme. For instance, MDL 72527 (compound 11) is an SMOspecific inhibitor and does not inhibit LSD1 activity. Contrary, GSK-LSD1 (3) is a
highly selective LSD1 inhibitor. Using each compound individually, we aimed to
distinguish the importance of LSD1 versus SMO in 9-mediated cardioprotection.
Sprague-Dawley rats were pretreated 1-hour prior to heart removal with
GSK-LSD1 (0.5 mg/kg, i.p.). GSK-LSD1 is an irreversible inhibitor with a fast
association constant. Therefore, it provided an effective method for confirmation
of LSD1 in preconditioning. GSK-LSD1 pressure traces substantiated our results
from 9 because they showed a significant recovery of LVEDP and LVDP (Figure
5.13).

Interestingly, at a concentration nearly 6-fold less (i.e. 0.5 mg/kg vs.

3mg/kg), GSK-LSD1 had a profound effect on pressure values following transient
global ischemia, with nearly a full recovery of function.
The results with GSK-LSD1, VLM, and 9 strongly suggested LSD1 was a
viable target to improve cardiac function following IR. However, to eliminate
doubt in the results seen by 9, we performed a negative control with an SMOspecific inhibitor. MDL 72527 was injected (30 mg/kg, i.p.) 1-hour prior to
excision of the heart. To our surprise, SMO inhibition had an overwhelming
benefit in the isolated heart (Figure 5.14). Immediately following reperfusion, the
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Figure 5.13. GSK-LSD1 (Compound 3); contractile recovery upon
reperfusion in isolated male rat hearts after 30mins ischemia. A
saline-filled balloon fixed to a pressure transducer measured contractile
function. Experimental group (n=3) were injected 1hr prior to ischemia with
0.5 mg/kg, i.p. with GSK-LSD1. *p<0.001. Mean ± SEM.
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Figure 5.14. MDL 72527 (Compound 11); contractile recovery upon
reperfusion in isolated male rat hearts after 30mins ischemia. A
saline-filled balloon fixed to a pressure transducer measured contractile
function. Experimental group (n=4) were injected 1hr prior to ischemia with
30 mg/kg, i.p. with MDL 72527. *p<0.001. Mean ± SEM.
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heart pressure traces reflected values similar to our baseline measurements.
Indeed, this implied that the 9 protective mechanisms might be through two
separate pathways. Of particular interest, we observed similar delays in onset of
peak rigor-contracture in both GSK-LSD1 and MDL72527 treatments. This
suggests that the general catalytic mechanisms of the family of amine oxidases
may be playing a collective role in acute energetics of cardiomyocytes.
Therefore, further evaluation needs to be addressed to understand this
phenomenon.
Despite the considerable improvement of functional pressure traces we
observed with individually targeting LSD1 and SMO, our dual inhibitor compound
9 did not demonstrate a similar effect.

In comparison, each inhibitor (i.e.

compound 9, MDL72527, GSK-LSD1, and VLM) improved LV developed
pressure to 80-100 mmHg after 1-hour of reperfusion (Figure 5.15). In addition,
they all sustained LV end diastolic pressure between 10-35 mmHg. Statistically,
a one-way ANOVA with Tukey multiple comparisons for each experimental group
showed no significant differences between each inhibitor.
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Figure 5.15. Left ventricle pressures of ischemic hearts following
60-minutes reperfusion. Experimental groups were injected 1-hour
prior to heart removal for retrograde perfusion. Transient global
ischemia was performed for 30-minutes. Compound 9 (3 mg/kg, i.p.);
MDL72527, 11 (30 mg/kg, i.p.); GSK-LSD1, 3 (0.5 mg/kg, i.p.);
Verlindamycin, 5 (3 mg/kg, i.p.). ψ p<0.001 Vehicle vs. No IR; *p<0.001
Experimental Treatment vs. Vehicle; NS = no significance between
experimental treatments. Mean ± SEM.
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LSD1 inhibition attenuates heart failure remodeling with reduced ejection fraction:
Chronic left ventricular remodeling takes place following reperfusion
therapy following an AMI.

In particular, fibrotic damage and eccentric

hypertrophy lead to reduced ejection fraction and eventually heart failure
(HFrEF). IR injury can potentiate heart failure with reduced ejection fraction.
Therefore, we hypothesized that LSD1 inhibition could attenuate this effect.
CD1 mice underwent a surgical model of IR injury by reversible ligation of
the left anterior descending (LAD) coronary artery. In short, the LAD was ligated
with 6-0 silk suture and PE-10 tubing for 40-min prior to reperfusion. At onset of
ischemia, compound 9 (3 mg/kg) or GSK-LSD1 (0.5 mg/kg) was injected
intraperitoneal. The PE-10 tubing was removed to simulate reperfusion of the
vasculature and the mouse was sutured for recovery. Two experimental groups
of mice were injected daily with an LSD1 inhibitor, one set with compound 9 and
the other with GSK-LSD1. A transthoracic echocardiogram was performed of
heart function prior to surgery and following the 7-day course of treatments
(Figure 5.16). Cardiac output, ejection fraction, fractional shortening, and LV
end diastolic diameter were calculated as previously described. Interestingly,
both LSD1 inhibitors better preserved the LV dilation expected from HFrEF
(Figure 5.17A). In addition, a significant recovery in ejection fraction and cardiac
output was observed (Figure 5.17A and B), as well as improved fractional
shortening (Figure 5.17B). Table 5.1 shows the absolute observed values 7days after IR surgery. Overall, these results demonstrate a role for LSD1targeted therapy in chronic heart failure remodeling.
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Figure 5.16. Transthoracic echocardiographs of 7-day IR study. The left anterior descending coronary artery
was ligated for 40-min prior to reperfusion. Compound 9 (3 mg/kg; i.p.) was injected at onset of ischemia. Mice
were injected daily with C1 for 1-week and analyzed by echocardiogram. Quantitative data for LVDs (red arrows)
and LVDd (yellow arrows) are shown. Heart function analysis by long-axis and short-axis views using a modified
Simpsons method before LAD ligation surgery and after 1- week post-surgery. Images represent
echocardiographs. LVDs = Left Ventricular Diameter at Systole; LVDd = Left Ventricular Diameter at Diastole.

A.

B.

Figure 5.17. Compound 9 and GSK-LSD1 reduction of chronic in vivo IR
injury cardiac remodeling. Male CD1 mice were anesthesized by 3%
isoflurane vaporized in 100% O2. The left anterior descending coronary artery
was ligated with 6-0 silk suture and PE-10 tubing for 40-min prior to
reperfusion. Compound 9 (3 mg/kg; i.p.) and GSK-LSD1 (0.5 mg/kg, i.p.) were
injected independently at onset of ischemia and daily for 7 days. Functional
analysis of the heart was performed by echocardiograph. Heart function
analysis was performed by long-axis and short-axis views using a modified
Simpsons method. * P-value <0.05 vs. Vehicle Sham IR; ns = Compound 9 vs.
GSK-LSD1. Table 5.1. shows the absolute values for these calculations.
Percent change calculated by (Final value – Initial Value)/Initial Value x 100.
Mean ± SEM.
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Table 5.1. Absolute values 7days post-IR (mean ± SEM) of in vivo LAD ligation-reperfusion with LSD1 inhibitors.

III. DISCUSSION
To date, no standard therapy exists that can mitigate the injury caused by
reperfusing an occluded coronary artery after an AMI. In fact, up to 50% of total
infarct damage is attributed to reperfusion injury.180 Upon reperfusion, localized
influx of oxidative stressors overwhelms the endogenous antioxidant systems
and leads to contractile dysfunction and arrhythmias. Eccentric hypertrophy is a
common outcome following an AMI.180 In particular, diffuse dilation of the LV with
reduced ejection fraction and cardiac output takes place following percutaneous
coronary intervention after an AMI. Current therapies (e.g. ACE inhibitors, beta
blockers, etc.) aim to prevent this chronic remodeling. In recent years, increasing
evidence indicates that epigenetic enzymes such as the histone demethylases
and deacetylases play crucial roles during CVD. One such enzyme, LSD1, is
hypoxia-inducible185 and regulates oxidative balance through epigenetic silencing
of oxidative scavenging enzymes and production of hydrogen peroxide.190 Yet,
the role LSD1 and other demethylase enzymes play in cardiac IR has yet to be
explored. Our goal was to identify LSD1 as a novel target to alleviate oxidative
damage and cardiac remodeling during cardiac IR injury. In particular, we utilized
our newly designed 3,5-diamino-1,2,4-triazolamine lead compound, 9, and other
amine oxidase-selective compounds to evaluate LSD1 in cardiac IR injury. The
results presented in this chapter show supporting evidence that reveals a histone
demethylase as a contributing factor to detrimental cardiac remodeling.
LSD1 and HDACs have been well characterized as cooperative
enzymes.191 In fact, catalytic activity of one can improve the binding efficiency of
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the other to its particular substrate. Forneris et al. showed that a synthetic 21-mer
peptidomimic of H3 N-terminus with acetyl-lysine increased the Km of LSD1 by
6-fold.192 In addition, many studies in cancer have shown in vitro changes in
histone acetylation by an LSD1 inhibitor (or vice versa with methylation) or the
sensitization of HDAC inhibition by means of LSD1 modulation.184-185,

193-194

Because there is a clear crosstalk between LSD1 and HDAC1/2, we were
interested in the benefit seen by HDAC inhibitors in reducing myocardial IR
damage182,

195

and the implications that LSD1 may also be contributory.

Therefore, we aimed to test a well-characterized LSD1 inhibitor in two murine
models of IR injury.
Our pilot study demonstrated that VLM, a noncompetitive inhibitor of LSD1
(IC50 = 8 µM), sustained cardiac function in an ex vivo isolated heart model
(Figure 5.3). VLM showed a beneficial phenotype when injected intraperitoneal
(3 mg/kg) at 1-hour prior to heart isolation. LV DP improved after reperfusion
because of an attenuation of the rise in LV EDP. In addition, we demonstrated
that total infarct area was reduced and that the preconditioning phenomenon was
not by classical RISK pro-survival signaling (Figure 5.4 and Figure 5.5). In fact,
there was a significant increase in phosphorylated p38. P38β has been shown to
contribute to anti-hypertrophic and anti-apoptotic signaling in the capacity of IR
injury189 However, p38 activation as a cardioprotective target is controversial
because it can also augment infarction.189 Although the exact mechanism
remains unclear, the timing of p38 activation and the isoform may play a role.
For instance, SB203580, a potent p38/MAPK inhibitor, shows both improvement
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when given prior to preconditioning and detriment when given during anoxia.196
Therefore, further testing needs to be performed to elucidate the possible role of
increased p-p38β.
One strategy to prevent the detrimental increases in H2O2 and O2- during
reperfusion is by enhancing the endogenous antioxidant enzymes catalase and
SOD2. One potential regulator of antioxidant expression is LSD1. For instance,
chromatin immunoprecipitation in diabetic retinopathy showed recruitment of
LSD1 to the SOD2 promoter, leading to changes in histone methylation and
modulation of SOD2 levels.186 Therefore, we observed whether targeting could
increase endogenous antioxidants (i.e. catalase and SOD2) in cardiac IR. In
animals pretreated with VLM, the protein levels of catalase significantly increased
post-IR (Figure 5.7A). Similar results were seen with class I specific inhibitors of
HDAC (HDAC1/2)182, a close functional counterpart to LSD1 within the
CoREST/REST co-repressor complex.
Despite the favorable results in our pilot study, our over-arching goal is to
develop compounds with attractive clinical potential and identify LSD1 as a
therapeutic target. Previous work with verlindamycin demonstrates a very low
therapeutic index (effective dose = 3mg/kg; lethal dose = 20mg/kg) and unabated
potency for other amine oxidases. Therefore, its utilization as a therapeutic in a
disease-state where cell death is not the desired endpoint is limited. Also, the
non-selectivity limits its usefulness as a tool to study LSD1.
As described in earlier chapters (Chapter 3 and 4), we’ve designed a
small molecule inhibitor (9) that demonstrates limited toxicity and is a more
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favorable cardiac drug candidate.

Like VLM, compound 9 improved similar

hemodynamic parameters and reduced total infarction in the ex vivo IR model
(Figure 5.10 and 5.12). Interestingly, we also observed a significant delay in
onset of peak rigor-contracture during anoxia (Figure 5.11). Rigor-contracture is
illustrated by a rise in end diastolic pressure with no developed pressure
approximately 15-20mins after total anoxia of the tissue. It is caused by the
insufficient supply of ATP to relinquish myosin heavy chains from actin filaments
and overload of Ca2+-bound troponin. Often, a delay in onset of rigor-contraction
is attributed to increased available high-energy phosphates or reduction in Ca2+overload.197 Therefore, this result indicates an ischemic protection versus a
reperfusion event, and thus, further testing needs to be performed (discussed
below).
Compound 9 also facilitated a significant mitigation of chronic systolic
dysfunction associated with an in vivo IR model when treated when given daily
for 7-days (Figure 5.16 and 5.17). In particular, the LV dilation that occurs from
eccentric hypertrophy leading to chronic HFrEF was significantly reduced. Of
note, the primary treatment with 9 was given immediately after the onset of
ischemia, and thus, exhibits a more clinically relevant scenario for patient
therapy. In other words, a patient with a new onset AMI can be treated postcoronary occlusion to assist with initial insult and chronic cardiac remodeling.
Aside from the physiologic benefit of 9, our goal was to identify
LSD1 as the causative target. However, as discussed in Chapter 4, compound 9
is a dual inhibitor of LSD1 and SMO. Therefore, we utilized enzyme selective
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inhibitors of each enzyme individually to dissect the mechanism of action of 9.
Interestingly, we demonstrated that both LSD1 and SMO inhibition in an acute ex
vivo experiment improved cardiac hemodynamic parameters (Figure 5.13 and
5.14). In addition, GSK-LSD1, the LSD1-selective inhibitor, also showed
analogous results to 9 in chronic improvement of systolic dysfunction (Figure
5.17). Of particular note, both GSK-LSD1 and MDL72527 demonstrated robust
delay in rigor-contracture (Figures 5.13 and 5.14). In fact, both inhibitors were
more effective in preventing the ischemic rise in EDP associated with rigorcontracture than 9. Clearly, further evaluation into the acute energetics of
cardiomyocytes needs to be addressed in future experiments to understand how
the amine oxidase family is improving the heart’s hypoxic response.
The individual roles LSD1 and SMO play during IR are still unclear.
However, we show three separate LSD1 inhibitors, including a highly potent and
selective LSD1 inhibitor, are protective in cardiac IR injury (Figure 5.15).
Therefore, our results suggest LSD1 is a viable therapeutic target to prevent IR
damage. The exact mechanisms behind this protective phenomenon are still
unclear.

IV. LIMITATIONS AND FUTURE DIRECTIONS
Despite the beneficial changes in the ex vivo isolated heart experiments
with LSD1 and SMO inhibitors, the acute administration of the drugs and lack of
global histone H3K4me2 changes (Figure 5.7B) suggest that the protective
effects of these compound were, in fact, a non-transcriptional event. Although
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less common, LSD1 has been shown to demethylate non-histone proteins.198
Also, there was a significant delay in onset of rigor contracture, advocating an
anoxic phenomenon versus the hypothesized reperfusion injury. Therefore,
future experiments will focus on the quantification of ATP/ADP and Ca2+transients during no-flow ischemia in the isolated heart. ATP/ADP can be
measured by a simple colorimetric assay (Abcam #ab83355) and Ca2+-transients
can be detected by whole cell voltage patch clamp in primary cardiomyocytes.
Not dissimilar, whole organ live imaging of voltage potential and calcium wave
propagation can be performed in the Langendorff preparation through
spatiotemporal optical mapping.199 Finally, if this phenomenon is an anoxiatriggered protection, a one-time bolus of compound given at ischemia (or just
prior to it) using the in vivo LAD ligation-reperfusion model should give similar
cardioprotective results 7-days after surgery.
As shown in Figure 5.15, inhibitors of LSD1 and SMO showed substantial
improvement in hemodynamic parameters. However, despite compound 9 being
efficacious against both enzymes, the effect seen was less pronounced, albeit
not statistically different from the other treatments. Compound 9 was the only
reversible, competitive inhibitor out of the four used in this assay. In particular,
MDL 72527 and GSK-LSD1 are covalent, “suicide” mechanism inhibitors. Thus, it
is highly possible that the diminished effect seen by 9 is simply due to enzyme
kinetics. In fact, an experimental group with compound 9 was injected at the
same dose as previously described, but at 4-hours prior to heart isolation
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(instead of 1-hour). Figure 5.18 demonstrates that a gradual loss in function
occurs during the period of reperfusion. We hypothesize that based on this

Figure 5.18. Compound 9 pretreated 4-hours prior to heart removal;
contractile recovery upon reperfusion in isolated male rat hearts after
30mins ischemia. A saline-filled balloon fixed to a pressure transducer
measured contractile function. Experimental group (n=3) were injected 4hr
prior to ischemia with 3 mg/kg, i.p. with 9. Mean ± SEM.

outcome, compound 9 may have a fast Koff rate or a very short-term effect.
Contrary, the irreversible inhibitors demonstrated no difference between 4- and
1-hour treatments (data not shown). One explanation for this is that irreversibly
inhibiting LSD1 with a highly potent inhibitor is sufficient enough in acute
treatments to noticeably ablate LSD1 activity. Thus, the only way the cells can
	
  

164	
  

recover is through expression turnover of the enzyme, which may be limited by
the isolated heart model. In short, the exact pharmacodynamics of compound 9
is unknown and as such, the tissue bioavailability is unclear. Future experiments
should be performed at various time points (i.e. 1-, 2-, and 3-hours prior to heart
isolation). Another strategy to address this issue is through a comprehensive
pharmacokinetic/pharmacodynamics screen.

However, we are reserving this

study for future lead optimized compound 9 derivatives.
LSD1 makes up just one of a vast multitude of histone demethylases in
the cell, some of which have similar substrates.200 Thus, LSD1 inhibition or
removal may not be detectable on a global histone level. In fact, many highly
potent LSD1 inhibitors fail to detect global methylation in certain cell lines on a
global scale. For instance, LSD1 knockout HCT116 cells failed to show any
changes in global histone methylation.201 Figure 5.7B corroborated this finding,
showing no changes in global methylation in homogenized whole isolated rat
hearts. LSD1 occupies approximately 2% of genomic promoters in corepressor
complexes in stem cells.202 LSD1 inhibition can alter gene transcription on a local
level,

without

showing

global

changes.

Therefore,

a

chromatin

immunoprecipitation (ChIP) of histone marks or key promoters may need to be
performed.
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Chapter 6: Overall Summary and Discussion
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Current treatments strategies for AMI continue to be palliative and aim to
prevent chronic remodeling through administration of post-insult ACE inhibitors
and beta-blockers. This strategy lowers total mortality and hospitalizations by
nearly 30% and hastens LV dysfunction.203 More importantly, prevention of longterm damage is best treated by fast restoration of flow to the occluded coronary
artery, often through thrombolytic therapy or primary percutaneous coronary
intervention.204 However, despite an improvement in outcomes with reperfusion
therapy, no standard pharmacological therapy exists that can mitigate the
unintentional damage caused by reperfusion injury. Recently, epigenetic
enzymes have become popular targets to limit IR damage and hypertrophic
remodeling.205 This dissertation identified a previously unexplored cardiac target,
the Lysine Specific Demethylase-1, as a completely new strategy to prevent IR
damage and chronic cardiac dysfunction. As such, we utilized structure-based
drug design as a tool to selectively target LSD1 and generated potent, nontoxic
LSD1-specific inhibitors with significant characteristics desirable as clinical
therapeutics.
LSD1 is overexpressed in a number of human cancers such as acute
myeloid leukemia, neuroblastoma, retinoblastoma, prostate cancer, breast
cancer, lung cancer and bladder cancer.206-209 Thus, the protein is traditionally an
important target for antitumor agents.210 However, new emerging roles for LSD1
in disease pathogenesis other than cancer are being reported.211-215 Thus, LSD1
has

become

a

promising

target

for

therapeutic

intervention.

The

tranylcypromine-based irreversible inhibitors (such as 2 and 3) are the most
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advanced chemical class with respect to drug development, and many
successful LSD1 inhibitors are derived from tranylcypromine scaffolds. However,
they rely on activation and/or covalent attachment to the FAD cofactor of LSD1.
Therefore, it is challenging to design selective LSD1 inhibitors that do not show
off-target effects mediated through	
   other flavin-dependent enzymes.216 The 3,5diamino-1,2,4-triazole motif described in this dissertation is the first presented
scaffold of its kind and supports the contention that potent, non-toxic LSD1specific inhibitors can be designed in this chemical class. To date, the structurally
diverse analogues utilizing this scaffold present the first reversible, competitive
inhibitors of LSD1.

Design of first reversible, competitive LSD1 inhibitors and their limited toxicity:
Chapter 3 and Chapter 4 describes the early process of hit-to-lead
optimization for compounds based on a 3,5-diamino-1,2,4-triazole scaffold. To
start, we applied a virtual screen of the Maybridge HitFinder 50,000 compound
library, which revealed structurally distinct drug-like compounds as potential
leads. Interestingly, compounds with primary amines, hydrophobic electron
withdrawing groups, and heterycycloalkyl groups were well represented in our
computational analysis. Two novel compounds, 9 and 10, were active with
IC50(LSD1) <2 µM (Figure 3.4) and demonstrated favourable proximity
interactions within 2.98Å of the FAD cofactor in the LSD1 active site (Figure 3.3).
These lead compounds were selected for future lead optimization and
biochemical characterization. A successful synthetic route to produce chemically
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diverse compounds was presented (Scheme 1) and a number of compounds
measured significant LSD1 inhibition (Table 3.2).

Therefore, these results

indicate a limited chemical library of 9 derivatives can be effectively synthesized
and is expected to contain multiple active compounds. We are continuing to
synthesize analogues in this series for the purpose of refining a structure/activity
model for 3,5-diamino-1,2,4-triazole-based LSD1 inhibitors. Also, analogues
containing functional groups designed to increase aqueous solubility are being
synthesized.
Of particular interest, we aimed to optimize compounds that showed
greater selectivity towards LSD1 and also demonstrated limited cytotoxicity,
making them ideal for studying LSD1 in the heart. Current inhibitors of amine
oxidases show significant undesirable potency towards other members of the
family. This is due, in part, because of the high sequence homology within the
active sites. Our initial evaluations of the selectivity of compounds 9 and 10
verified they possessed selectivity for LSD1 over MAO A and B (Selectivity Index
>100) (Figure 4.2). Also, compound 9 revealed competitive enzyme kinetics
(Figure 3.6), establishing it as the first small molecule scaffold of a reversible,
competitive LSD1 inhibitor.
Many current LSD1 inhibitors have been designed as antitumor agents
and demonstrate significant toxicity to cells. We were interested in the role of
LSD1 in CVD, and thus, intended to manipulate epigenetic enzymes without
causing drug-driven cellular damage. In Chapter 4, we presented evidence that
3,5-diamino-1,2,4-triazoles showed limited in vitro and in vivo toxicity. In
	
  

169	
  

particular, a short 7-day toxicology study revealed minimal to mild histological
damage to the kidney, liver, and heart. The low level of toxicity to mammalian
cells and CD1 mice demonstrate that the 1,2,4-triazole scaffold can be utilized to
produce LSD1 inhibitors for diseases without desirable cell death.

Selective compounds reveal LSD1 as a novel cardiac therapeutic target:
The induction of LSD1 activity and expression during hypoxia has been
previously explored in cancer217, DNA mismatch repair mechanisms218, and
global cerebral ischemia.219 Thus, we explored the responsiveness of LSD1
within hypoxic tissue distal to an occluded coronary artery. Our results showed a
significant increase in LSD1 protein (Figure 5.2A) and notably, the expression of
LSD1 correlated to cardiac systolic function (Figure 5.2B and C). As such, we
hypothesized that LSD1 could be a new responsive therapeutic for an AMI.
Evidence in the literature supported the notion that LSD1 could be a viable
target in mitigation of cardiac damage after an ischemic event. Traditional
mechanisms of action on histones involved discrete, individual activities of
HDACs and LSD1 on lysine tails. However, increasing evidence is showing that
residue modifications are dependent on interplay between the vast milieu of
epigenetic enzymes. In fact, LSD1 and HDACs have been recently characterized
as cooperative enzymes,220 where catalytic activity of one can improve the
binding efficiency of the other to its particular substrate. Forneris et al. showed
that a synthetic 21-mer peptidomimic of H3 N-terminus with acetyl-lysine
increased the Km of LSD1 by 6-fold.221 Because there is a clear crosstalk
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between LSD1 and HDAC1/2, we were interested in the benefit seen by HDAC
inhibitors in reducing myocardial IR damage222-223 and the implications that LSD1
may also be contributory.
Early experiments with a noncompetitive, nonselective LSD1 inhibitor
(VLM, Figure 5.3) were successful in maintaining acute cardiac hemodynamic
parameters following transient global IR. Using an ex vivo isolated heart model,
we successfully reproduced these results with compound 9 and treated with a
significantly less effective dose (Figure 5.10). With both compounds, we saw a
significant improvement in LV developed pressure, LV end diastolic pressure,
and a reduction in the total infarct cross-sectional area (Figure 5.12).
As discussed in Chapter 4, compound 9 is a dual inhibitor of LSD1 and
SMO, and thus, it was difficult to draw conclusions for the mechanism of action of
9. Therefore, we utilized enzyme selective inhibitors of each enzyme individually
to dissect the mechanism of action of 9. GSK-LSD1 is a recent commercially
available, highly selective LSD1 irreversible inhibitor224 and MDL 72527 is a well
characterized irreversible SMO inactivator.225 Interestingly, we demonstrated that
both LSD1 and SMO inhibition in an acute ex vivo experiment improved cardiac
function (Figure 5.13 and 5.14).
Of note, we observed a significant delay of onset in peak rigor-contracture
during no-flow ischemia with all three compounds (Figure 5.11).

Rigor-

contracture is caused by the insufficient supply of ATP to relinquish myosin
heavy chains from actin filaments and overload of Ca2+-bound troponin. Often, a
delay in onset of rigor-contraction is attributed to increased available high-energy
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phosphates or reduction in Ca2+-overload.226 Therefore, this result indicates an
ischemic protection versus a reperfusion event. Clearly, further evaluation into
the acute energetics of cardiomyocytes needs to be addressed in future
experiments to understand how the amine oxidase family is improving the heart’s
hypoxic response.
Our observations in the Langendorff isolated hearts was crucial in our
understanding of acute management of IR injury. However, it failed to show longterm cardiac outcomes and cardiac remodeling.

We implemented a more

clinically relevant in vivo LAD ligation-reperfusion model of IR (see Chapter 2 –
“Left anterior descending coronary ligation-reperfusion in vivo IR”). This model
causes LV dilation and reduced ejection fraction similar to clinical manifestations
from eccentric hypertrophy and chronic HFrEF. Compound 9 and GSK-LSD1
both facilitated a significant mitigation of chronic systolic dysfunction (Figure
5.17). Most importantly, primary treatment was given immediately after the onset
of ischemia, and thus, exhibits a more clinically relevant scenario for patient
therapy. In other words, a patient with a new onset AMI can be treated postcoronary occlusion to assist with initial insult and chronic cardiac remodeling.

Conclusions and final thoughts:
We successfully designed a novel scaffold of reversible, competitive LSD1
inhibitors that show limited cytotoxicity. One compound, 9, was advanced into
preclinical testing and was effective in sustaining cardiac structure and function.
We presented evidence utilizing selective inhibitors for the two enzymes
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modulated by 9 as tools to reveal LSD1 as a novel therapeutic target in CVD.
More additional lead optimization studies are currently being performed that will
lead to derivatives of 9 with improved pharmacodynamics/pharmacokinetic
parameters and higher potency for LSD1.
Overall, LSD1 plays a previously unexplored role in cardiovascular
disease. Although the exact mechanism is still unclear, continued experiments
with LSD1 selective inhibitors, such as GSK-LSD1 or 9 derivatives, should reveal
a highly coordinated effort by epigenetic complexes in tissue damage and
remodeling.
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